Document And Entity Information
Document And Entity Information - shares | 6 Months Ended | |
Jun. 30, 2020 | Aug. 12, 2020 | |
Document Information [Line Items] | ||
Entity Registrant Name | VIVEVE MEDICAL, INC. | |
Entity Central Index Key | 0000879682 | |
Trading Symbol | vive | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Non-accelerated Filer | |
Entity Current Reporting Status | Yes | |
Entity Emerging Growth Company | false | |
Entity Small Business | true | |
Entity Interactive Data Current | Yes | |
Entity Common Stock, Shares Outstanding (in shares) | 15,734,058 | |
Entity Shell Company | false | |
Document Type | 10-Q | |
Document Period End Date | Jun. 30, 2020 | |
Document Fiscal Year Focus | 2020 | |
Document Fiscal Period Focus | Q2 | |
Amendment Flag | false | |
Title of 12(b) Security | Common Stock |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) | Jun. 30, 2020 | Dec. 31, 2019 | |
Current assets: | |||
Cash and cash equivalents | $ 8,500,000 | $ 13,308,000 | [1] |
Accounts receivable, net of allowance for doubtful accounts of $463 and $407 as of June 30, 2020 and December 31, 2019, respectively | 1,017,000 | 1,573,000 | [1] |
Inventory | 4,917,000 | 4,861,000 | [1] |
Prepaid expenses and other current assets | 1,921,000 | 2,447,000 | [1] |
Total current assets | 16,355,000 | 22,189,000 | [1] |
Property and equipment, net | 2,853,000 | 3,046,000 | [1] |
Investment in limited liability company | 948,000 | 1,216,000 | [1] |
Other assets | 376,000 | 526,000 | [1] |
Total assets | 20,532,000 | 26,977,000 | [1] |
Current liabilities: | |||
Accounts payable | 1,257,000 | 1,608,000 | [1] |
Accrued liabilities | 2,835,000 | 4,698,000 | [1] |
Paycheck Protection Program loan, current portion | 559,000 | ||
Total current liabilities | 4,651,000 | 6,306,000 | [1] |
Note payable, noncurrent portion | 4,241,000 | 3,983,000 | [1] |
Paycheck Protection Program loan, noncurrent portion | 784,000 | ||
Other noncurrent liabilities | 229,000 | 167,000 | [1] |
Total liabilities | 9,905,000 | 10,456,000 | [1] |
Commitments and contingences (Note 9) | |||
Stockholders’ equity: | |||
Common stock, $0.0001 par value; 75,000,000 shares authorized as of June 30, 2020 and December 31, 2019; 15,734,058 and 7,075,684 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively | 2,000 | 1,000 | [1] |
Additional paid-in capital | 221,961,000 | 214,431,000 | [1] |
Accumulated deficit | (211,336,000) | (197,911,000) | [1] |
Total stockholders’ equity | 10,627,000 | 16,521,000 | [1] |
Total liabilities and stockholders’ equity | 20,532,000 | 26,977,000 | [1] |
Series A Preferred Stock [Member] | |||
Stockholders’ equity: | |||
Convertible preferred stock | |||
Series B Preferred Stock [Member] | |||
Stockholders’ equity: | |||
Convertible preferred stock | [1] | ||
[1] | The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date. |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands | Jun. 30, 2020 | Dec. 31, 2019 | |
Accounts receivable, allowance for doubtful accounts | $ 463 | $ 407 | [1] |
Convertible preferred stock, shares authorized (in shares) | 10,000,000 | 10,000,000 | |
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 | [1] |
Common stock, shares authorized (in shares) | 75,000,000 | 75,000,000 | [1] |
Common stock, shares issued (in shares) | 15,734,058 | 7,075,684 | [1] |
Common stock, shares outstanding (in shares) | 15,734,058 | 7,075,684 | [1] |
Series A Preferred Stock [Member] | |||
Convertible preferred stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 | |
Convertible preferred stock, shares issued (in shares) | 0 | 1,852,173 | |
Convertible preferred stock, shares outstanding (in shares) | 0 | 1,852,173 | |
Series B Preferred Stock [Member] | |||
Convertible preferred stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 | [1] |
Convertible preferred stock, shares issued (in shares) | 33,685 | 31,678 | [1] |
Convertible preferred stock, shares outstanding (in shares) | 33,685 | 31,678 | [1] |
[1] | The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date. |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | |
Revenue | $ 704,000 | $ 1,052,000 | $ 2,008,000 | $ 4,064,000 |
Cost of revenue | 1,071,000 | 941,000 | 2,200,000 | 2,882,000 |
Gross profit (loss) | (367,000) | 111,000 | (192,000) | 1,182,000 |
Operating expenses: | ||||
Research and development | 1,224,000 | 2,902,000 | 2,862,000 | 5,382,000 |
Selling, general and administrative | 3,350,000 | 5,530,000 | 7,715,000 | 12,156,000 |
Restructuring costs | 742,000 | |||
Total operating expenses | 4,574,000 | 8,432,000 | 10,577,000 | 18,280,000 |
Loss from operations | (4,941,000) | (8,321,000) | (10,769,000) | (17,098,000) |
Modification of Series A and B warrants | (1,838,000) | (1,838,000) | ||
Interest expense, net | (223,000) | (1,194,000) | (433,000) | (2,310,000) |
Other expense, net | (27,000) | (71,000) | (117,000) | (82,000) |
Net loss from consolidated companies | (7,029,000) | (9,586,000) | (13,157,000) | (19,490,000) |
Loss from minority interest in limited liability company | (86,000) | (138,000) | (268,000) | (263,000) |
Comprehensive and net loss | (7,115,000) | (9,724,000) | (13,425,000) | (19,753,000) |
Series B convertible preferred stock dividends | (1,021,000) | (2,011,000) | ||
Net loss attributable to common stockholders | $ (8,136,000) | $ (9,724,000) | $ (15,436,000) | $ (19,753,000) |
Net loss per share of common stock: | ||||
Basic and diluted (in dollars per share) | $ (0.57) | $ (20.93) | $ (1.34) | $ (42.54) |
Weighted average shares used in computing net loss per common share: | ||||
Basic and diluted (in shares) | 14,186,199 | 464,638 | 11,558,472 | 464,321 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands | November 2019 Offering [Member]Preferred Stock [Member]Series A Preferred Stock [Member] | November 2019 Offering [Member]Preferred Stock [Member]Series B Preferred Stock [Member] | November 2019 Offering [Member]Common Stock [Member] | November 2019 Offering [Member]Additional Paid-in Capital [Member] | November 2019 Offering [Member]Retained Earnings [Member] | November 2019 Offering [Member] | Purchase Agreement with LPC [Member]Preferred Stock [Member]Series A Preferred Stock [Member] | Purchase Agreement with LPC [Member]Preferred Stock [Member]Series B Preferred Stock [Member] | Purchase Agreement with LPC [Member]Common Stock [Member] | Purchase Agreement with LPC [Member]Additional Paid-in Capital [Member] | Purchase Agreement with LPC [Member]Retained Earnings [Member] | Purchase Agreement with LPC [Member] | Series A Warrants [Member]Preferred Stock [Member]Series A Preferred Stock [Member] | Series A Warrants [Member]Preferred Stock [Member]Series B Preferred Stock [Member] | Series A Warrants [Member]Common Stock [Member] | Series A Warrants [Member]Additional Paid-in Capital [Member] | Series A Warrants [Member]Retained Earnings [Member] | Series A Warrants [Member] | Series B Warrants [Member]Preferred Stock [Member]Series A Preferred Stock [Member] | Series B Warrants [Member]Preferred Stock [Member]Series B Preferred Stock [Member] | Series B Warrants [Member]Common Stock [Member] | Series B Warrants [Member]Additional Paid-in Capital [Member] | Series B Warrants [Member]Retained Earnings [Member] | Series B Warrants [Member] | Director [Member]Preferred Stock [Member]Series A Preferred Stock [Member] | Director [Member]Preferred Stock [Member]Series B Preferred Stock [Member] | Director [Member]Common Stock [Member] | Director [Member]Additional Paid-in Capital [Member] | Director [Member]Retained Earnings [Member] | Director [Member] | Consultant [Member]Preferred Stock [Member]Series A Preferred Stock [Member] | Consultant [Member]Preferred Stock [Member]Series B Preferred Stock [Member] | Consultant [Member]Common Stock [Member] | Consultant [Member]Additional Paid-in Capital [Member] | Consultant [Member]Retained Earnings [Member] | Consultant [Member] | Employees [Member]Preferred Stock [Member]Series A Preferred Stock [Member] | Employees [Member]Preferred Stock [Member]Series B Preferred Stock [Member] | Employees [Member]Common Stock [Member] | Employees [Member]Additional Paid-in Capital [Member] | Employees [Member]Retained Earnings [Member] | Employees [Member] | Preferred Stock [Member]Series A Preferred Stock [Member] | Preferred Stock [Member]Series B Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Series B Preferred Stock [Member] | Total | |
Balances (in shares) at Dec. 31, 2018 | 463,630 | |||||||||||||||||||||||||||||||||||||||||||||||||
Balances at Dec. 31, 2018 | $ 160,297 | $ (155,385) | $ 4,912 | |||||||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation expense | 470 | 470 | ||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of common shares from employee stock purchase plan (in shares) | 429 | |||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of common shares from employee stock purchase plan | 35 | 35 | ||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of restricted common shares in connection with consulting agreement (in shares) | 274 | |||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of restricted common shares in connection with consulting agreement | 25 | 25 | ||||||||||||||||||||||||||||||||||||||||||||||||
Net loss | (10,029) | (10,029) | ||||||||||||||||||||||||||||||||||||||||||||||||
Restricted stock awards (in shares) | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||
Restricted stock awards | 1 | 1 | ||||||||||||||||||||||||||||||||||||||||||||||||
Balances (in shares) at Mar. 31, 2019 | 464,339 | |||||||||||||||||||||||||||||||||||||||||||||||||
Balances at Mar. 31, 2019 | 160,828 | (165,414) | (4,586) | |||||||||||||||||||||||||||||||||||||||||||||||
Balances (in shares) at Dec. 31, 2018 | 463,630 | |||||||||||||||||||||||||||||||||||||||||||||||||
Balances at Dec. 31, 2018 | 160,297 | (155,385) | 4,912 | |||||||||||||||||||||||||||||||||||||||||||||||
Net loss | (19,753) | |||||||||||||||||||||||||||||||||||||||||||||||||
Balances (in shares) at Jun. 30, 2019 | 465,722 | |||||||||||||||||||||||||||||||||||||||||||||||||
Balances at Jun. 30, 2019 | 161,469 | (175,138) | (13,669) | |||||||||||||||||||||||||||||||||||||||||||||||
Balances (in shares) at Dec. 31, 2018 | 463,630 | |||||||||||||||||||||||||||||||||||||||||||||||||
Balances at Dec. 31, 2018 | 160,297 | (155,385) | 4,912 | |||||||||||||||||||||||||||||||||||||||||||||||
Series B convertible preferred stock dividends paid in PIK shares (in shares) | 378 | |||||||||||||||||||||||||||||||||||||||||||||||||
Balances (in shares) at Dec. 31, 2019 | 1,852,173 | 31,678 | 7,075,684 | |||||||||||||||||||||||||||||||||||||||||||||||
Balances at Dec. 31, 2019 | $ 1 | 214,431 | (197,911) | 16,521 | [1] | |||||||||||||||||||||||||||||||||||||||||||||
Balances (in shares) at Mar. 31, 2019 | 464,339 | |||||||||||||||||||||||||||||||||||||||||||||||||
Balances at Mar. 31, 2019 | 160,828 | (165,414) | (4,586) | |||||||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation expense | 562 | 562 | ||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of common shares from employee stock purchase plan (in shares) | 602 | |||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of common shares from employee stock purchase plan | 20 | 20 | ||||||||||||||||||||||||||||||||||||||||||||||||
Net loss | (9,724,000) | (9,724) | ||||||||||||||||||||||||||||||||||||||||||||||||
Restricted stock awards (in shares) | 525 | 250 | 6 | |||||||||||||||||||||||||||||||||||||||||||||||
Restricted stock awards | $ 48 | $ 48 | $ 11 | $ 11 | ||||||||||||||||||||||||||||||||||||||||||||||
Balances (in shares) at Jun. 30, 2019 | 465,722 | |||||||||||||||||||||||||||||||||||||||||||||||||
Balances at Jun. 30, 2019 | 161,469 | (175,138) | (13,669) | |||||||||||||||||||||||||||||||||||||||||||||||
Balances (in shares) at Dec. 31, 2019 | 1,852,173 | 31,678 | 7,075,684 | |||||||||||||||||||||||||||||||||||||||||||||||
Balances at Dec. 31, 2019 | $ 1 | 214,431 | (197,911) | 16,521 | [1] | |||||||||||||||||||||||||||||||||||||||||||||
Issuance costs | $ (30) | $ (30) | ||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Series A convertible preferred stock into common stock (in shares) | (1,852,173) | 1,852,173 | ||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Series A convertible preferred stock into common stock | ||||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of common shares in connection with warrant exercises (in shares) | 1,026,240 | 45,473 | ||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of common shares in connection with warrant exercises | $ 1,591 | $ 1,591 | $ 70 | $ 70 | ||||||||||||||||||||||||||||||||||||||||||||||
Series B convertible preferred stock dividends | (990) | (990) | ||||||||||||||||||||||||||||||||||||||||||||||||
Series B convertible preferred stock dividends paid in PIK shares (in shares) | 989 | |||||||||||||||||||||||||||||||||||||||||||||||||
Series B convertible preferred stock dividends paid in PIK shares | 989 | 989 | ||||||||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation expense | 686 | 686 | ||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of common shares from employee stock purchase plan (in shares) | 320 | |||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of common shares from employee stock purchase plan | ||||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of restricted common shares in connection with consulting agreement (in shares) | 28,313 | |||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of restricted common shares in connection with consulting agreement | 24 | 24 | ||||||||||||||||||||||||||||||||||||||||||||||||
Net loss | (6,310) | (6,310) | ||||||||||||||||||||||||||||||||||||||||||||||||
Balances (in shares) at Mar. 31, 2020 | 32,667 | 10,028,203 | ||||||||||||||||||||||||||||||||||||||||||||||||
Balances at Mar. 31, 2020 | $ 1 | 216,771 | (204,221) | 12,551 | ||||||||||||||||||||||||||||||||||||||||||||||
Balances (in shares) at Dec. 31, 2019 | 1,852,173 | 31,678 | 7,075,684 | |||||||||||||||||||||||||||||||||||||||||||||||
Balances at Dec. 31, 2019 | $ 1 | 214,431 | (197,911) | 16,521 | [1] | |||||||||||||||||||||||||||||||||||||||||||||
Series B convertible preferred stock dividends paid in PIK shares (in shares) | 2,007 | |||||||||||||||||||||||||||||||||||||||||||||||||
Net loss | (13,425) | |||||||||||||||||||||||||||||||||||||||||||||||||
Balances (in shares) at Jun. 30, 2020 | 33,685 | 15,734,058 | ||||||||||||||||||||||||||||||||||||||||||||||||
Balances at Jun. 30, 2020 | $ 2 | 221,961 | (211,336) | 10,627 | ||||||||||||||||||||||||||||||||||||||||||||||
Balances (in shares) at Mar. 31, 2020 | 32,667 | 10,028,203 | ||||||||||||||||||||||||||||||||||||||||||||||||
Balances at Mar. 31, 2020 | $ 1 | 216,771 | (204,221) | 12,551 | ||||||||||||||||||||||||||||||||||||||||||||||
Issuance costs | $ (3) | $ (3) | $ (452) | $ (452) | ||||||||||||||||||||||||||||||||||||||||||||||
Issuance of common shares in connection with warrant exercises (in shares) | 4,852,284 | 293,490 | ||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of common shares in connection with warrant exercises | $ 1 | 2,959 | 2,960 | 179 | 179 | |||||||||||||||||||||||||||||||||||||||||||||
Series B convertible preferred stock dividends | (1,021) | (1,021) | ||||||||||||||||||||||||||||||||||||||||||||||||
Series B convertible preferred stock dividends paid in PIK shares (in shares) | 1,018 | 1,018 | ||||||||||||||||||||||||||||||||||||||||||||||||
Series B convertible preferred stock dividends paid in PIK shares | 1,018 | 1,018 | ||||||||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation expense | 632 | 632 | ||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of common shares from employee stock purchase plan (in shares) | 300 | |||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of common shares from employee stock purchase plan | ||||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of restricted common shares in connection with consulting agreement (in shares) | 34,531 | |||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of restricted common shares in connection with consulting agreement | 25 | 25 | ||||||||||||||||||||||||||||||||||||||||||||||||
Net loss | (7,115) | (7,115) | ||||||||||||||||||||||||||||||||||||||||||||||||
Modification of warrants in connection with 2020 Warrant Offering | $ 997 | $ 997 | $ 841 | $ 841 | ||||||||||||||||||||||||||||||||||||||||||||||
Issuance of Series A-2 and B-2 warrants in connection with 2020 Warrant Offering | 1,838 | 1,838 | ||||||||||||||||||||||||||||||||||||||||||||||||
Issuance costs for Series A-2 and B-2 warrants in connection with 2020 Warrant Offering | (1,838) | (1,838) | ||||||||||||||||||||||||||||||||||||||||||||||||
Transaction costs in connection with 2020 Warrant Offering | (326) | (326) | ||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of initial purchase common shares under the Purchase Agreement with LPC (in shares) | 525,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of initial purchase common shares under the Purchase Agreement with LPC | 341 | 341 | ||||||||||||||||||||||||||||||||||||||||||||||||
Restricted stock awards (in shares) | 250 | |||||||||||||||||||||||||||||||||||||||||||||||||
Restricted stock awards | ||||||||||||||||||||||||||||||||||||||||||||||||||
Balances (in shares) at Jun. 30, 2020 | 33,685 | 15,734,058 | ||||||||||||||||||||||||||||||||||||||||||||||||
Balances at Jun. 30, 2020 | $ 2 | $ 221,961 | $ (211,336) | $ 10,627 | ||||||||||||||||||||||||||||||||||||||||||||||
[1] | The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date. |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 6 Months Ended | |
Jun. 30, 2020 | Jun. 30, 2019 | |
Cash flows from operating activities: | ||
Net loss | $ (13,425,000) | $ (19,753,000) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Provision for doubtful accounts and write off of accounts receivable | 229,000 | 185,000 |
Depreciation and amortization | 651,000 | 547,000 |
Stock-based compensation | 1,367,000 | 1,117,000 |
Non-cash interest expense | 258,000 | 843,000 |
Amortization of operating lease right-of-use assets and accretion of operating lease liabilities | 5,000 | 5,000 |
Loss from minority interest in limited liability company | 268,000 | 263,000 |
Loss on disposal of property and equipment | 65,000 | |
Modification of Series A and B warrants | 1,838,000 | |
Changes in assets and liabilities: | ||
Accounts receivable | 327,000 | 1,963,000 |
Inventory | (222,000) | (299,000) |
Prepaid expenses and other current assets | 526,000 | (210,000) |
Other noncurrent assets | 417,000 | 40,000 |
Accounts payable | (351,000) | (2,388,000) |
Accrued and other liabilities | (2,132,000) | (1,736,000) |
Other noncurrent liabilities | 55,000 | 104,000 |
Net cash used in operating activities | (10,189,000) | (19,254,000) |
Cash flows from investing activities: | ||
Purchase of property and equipment | (292,000) | (718,000) |
Net cash used in investing activities | (292,000) | (718,000) |
Cash flows from financing activities: | ||
Proceeds from exercise of Series A and B common warrants | 4,800,000 | |
Transaction costs in connection with 2020 Warrant Offering | (326,000) | |
Proceeds from Paycheck Protection Program loan | 1,343,000 | |
Proceeds from intial purchase of common shares under Purchase Agreement with LPC | 341,000 | |
Proceeds from issuance of common shares from employee stock purchase plan | 55,000 | |
Transaction costs in connection with note payable | (100,000) | |
Net cash provided by financing activities | 5,673,000 | (45,000) |
Net decrease in cash and cash equivalents | (4,808,000) | (20,017,000) |
Cash and cash equivalents - beginning of period | 13,308,000 | 29,523,000 |
Cash and cash equivalents - end of period | 8,500,000 | 9,506,000 |
Supplemental disclosure: | ||
Cash paid for interest | 1,364,000 | |
Cash paid for income taxes | ||
Supplemental disclosure of cash flow information as of end of period: | ||
Issuance of Series B convertible preferred stock in settlement of dividends | 2,007,000 | |
Issuance of note payable in settlement of accrued interest | 256,000 | |
Net transfer of equipment between inventory and property and equipment | 166,000 | (296,000) |
Operating cash outflows from operating leases | 150,000 | 73,000 |
Right-of-use assets obtained in exchange for operating lease liabilities (upon adoption of ASC 842) | 629,000 | |
November 2019 Offering [Member] | ||
Cash flows from financing activities: | ||
Transaction costs in connection with November 2019 Offering | (33,000) | |
Purchase Agreement with LPC [Member] | ||
Cash flows from financing activities: | ||
Transaction costs in connection with November 2019 Offering | $ (452,000) |
Note 1 - The Company and Basis
Note 1 - The Company and Basis of Presentation | 6 Months Ended |
Jun. 30, 2020 | |
Notes to Financial Statements | |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | 1. The Company and Basis of Presentation Viveve Medical, Inc. (“Viveve Medical”, the “Company”, “we”, “our”, or “us”) designs, develops, manufactures and markets a platform medical technology, which we refer to as Cryogen-cooled Monopolar RadioFrequency Purchase Agreement with Lincoln Park Capital, LLC On June 8, 2020, $10,000,000 30 On June 9, 2020, 525,000 $0.65 may 250,000 500,000 11 no Other than as described above and Note 11 no 2020 On April 15, 2020, $1.55 $0.61 April 16, 2020, 4,820,584 242,790 $3,089,000. 2 4,820,584 2 242,790 $0.6371 five April 20, 2020. 2020 $326,000. 11 2 2 2019 In November 2019, “November 2019 $11,500,000, $9,922,000. A total of 1,945,943 5,473,410 7,419,353 7,419,353 June 30, 2020, no June 30, 2020, 1,540,829 7,080,390 10 11 In connection with the closing of the November 2019 $28,981,000 $31,300,000, 31,300 9,893,776 6 Interim Unaudited Financial Information The accompanying unaudited condensed consolidated financial statements of Viveve Medical have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10 8 03 X. not The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Annual Report on Form 10 December 31, 2019, March 19, 2020. six June 30, 2020 not December 31, 2020 Liquidity and Management Plans The Company has adopted the Financial Accounting Standards Board's (“FASB”) Accounting Standard Codification (“ASC”) Topic 205 40, one The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. However, since inception, the Company has sustained significant operating losses and such losses are expected to continue for the foreseeable future. As of June 30, 2020, $211,336,000, $8,500,000 $11,704,000. $10,189,000 six June 30, 2020. August 2021. not one To fund further operations, the Company will need to raise additional capital. The Company may no not no no |
Note 2 - Summary of Significant
Note 2 - Summary of Significant Accounting Policies | 6 Months Ended |
Jun. 30, 2020 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | 2. Summary of Significant Accounting Policies Financial Statement Presentation The condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation. Reverse Stock Split The Company effected a 1 100 September 18, 2019. not No $6,000. The par value of the Company's common stock remained unchanged at $0.0001 The number of authorized shares of common stock remained at 75,000,000. The reverse stock split proportionately affected the number of shares of common stock available for issuance under the Company's equity incentive plans. All stock options, warrants and restricted stock awards of the Company outstanding shares immediately prior to the reverse stock split were adjusted in accordance with their terms. On the effective date of the reverse stock split, (i) each 100 one 100 1 1 100 100 1 All of the share numbers, share prices, and exercise prices have been adjusted, on a retroactive basis, to reflect this 1 100 Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three one may, Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no Most of the Company's products to date require clearance or approvals from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commencing commercial sales. There can be no The Company is subject to risks common to companies in the medical device industry including, but not The Company designs, develops, manufactures and markets a medical device that it refers to as the Viveve System, which is intended for the non-invasive treatment of vaginal introital laxity, for improved sexual function, for vaginal rejuvenation, for use in general surgical procedures for electrocoagulation and hemostasis, and stress urinary incontinence, depending on the relevant country-specific clearance or approval. The Viveve System consists of three four five third In North America, the Company sells its products primarily through a direct sales force to health care practitioners. Outside North America, the Company sells through an extensive network of distribution partners. During the three June 30, 2020, three 74% three June 30, 2019, three 55% six June 30, 2020, one 49% six June 30, 2019, two 32% There were no 10% three six June 30, 2020 2019. As of June 30, 2020, one 21% December 31, 2019, two 49% Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and are not six may six not $463,000 June 30, 2020 $407,000 December 31, 2019. During the three six June 30, 2020, $173,000 no three six June 30, 2019. Revenue from Contracts with Customers Revenue consists primarily of the sale of the Viveve System, single-use treatment tips and ancillary consumables. The Company applies the following five 1 2 3 4 5 Rental revenue is generated through the lease of the Viveve System. The Company's operating leases for the Viveve System generally have a rental period of six nine June 30, 2019 not June 30, 2020 December 31, 2019, $804,000 $662,000, three six June 30, 2020, $6,000 $303,000, December 31, 2019. Late in the first 2020, 19 70 80% three 19 In connection with the lease of the Viveve System, the Company offers single-use treatment tips and ancillary consumables that are considered non-lease components. In the contracts with lease and non-lease components, the Company follows the relevant guidance in ASC 606, Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance for differing indications, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Latin America, Europe, the Middle East and Asia Pacific. In North America, we market and sell primarily through a direct sales force. Outside of North America, we market and sell primarily through distribution partners. The Company does not Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer advance payment from accrued liabilities when revenue is recognized upon shipment of the products. Contract Assets and Liabilities The Company continually evaluates whether the revenue generating activities and advanced payment arrangements with customers result in the recognition of contract assets or liabilities. No June 30, 2020 December 31, 2019. $21,000 $108,000, not June 30, 2020 December 31, 2019, three six June 30, 2020, $4,000 $87,000, December 31, 2019. The following table reflects the changes in our customer contract liabilities for the six June 30, 2020: June 30, December 31, 2020 2019 Change Customer contracts liabilities: Marketing programs $ 21 $ 108 $ (87 ) Total $ 21 $ 108 $ (87 ) Separately, accounts receivable, net represents receivables from contracts with customers. Significant Financing Component The Company applies the practical expedient to not not one three six June 30, 2020 2019, not Contract Costs The Company expects that commissions paid to obtain subscriptions are recoverable and has therefore capitalized them as a contract costs in the amount of $102,000 $337,000 June 30, 2020 December 31, 2019, June 30, 2019 no three June 30, 2019. three June 30, 2020 2019, $133,000 zero, six June 30, 2020 2019, $331,000 zero no one Shipping and Handling Shipping costs billed to customers are recorded as revenue. Shipping and handling expense related to costs incurred to deliver product are recognized within cost of goods sold. The Company accounts for shipping and handling activities that occur after control has transferred as a fulfillment cost as opposed to a separate performance obligation, and the costs of shipping and handling are recognized concurrently with the related revenue. Revenue by Geographic Area Management has determined that the sales by geography is a key indicator for understanding the Company's financials because of the different sales and business models that are required in the various regions of the world (including regulatory, selling channels, pricing, customers and marketing efforts). The following table presents the revenue from unaffiliated customers disaggregated by geographic area for the three six June 30, 2020 2019 Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 North America $ 116 $ 663 $ 804 $ 2,455 Asia Pacific 588 343 1,185 1,310 Europe and Middle East - 43 5 289 Latin America - 3 14 10 Total $ 704 $ 1,052 $ 2,008 $ 4,064 The Company determines geographic location of its revenue based upon the destination of the shipments of its products. Investments in Unconsolidated Affiliates The Company uses the equity method to account for its investments in entities that it does not 1 2 3 three not The Company assesses the potential impairment of the equity method investments when indicators such as a history of operating losses, a negative earnings and cash flow outlook, and the financial condition and prospects for the investee's business segment might indicate a loss in value. The carrying value of the investments is reviewed annually for changes in circumstances or the occurrence of events that suggest the investment may not No three six June 30 , 2020 2019. Product Warranty The Company's products sold to customers are generally subject to warranties between one three not Accounting for Stock-Based Compensation Share-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the employee's service period. The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award. The Company determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair value for stock options and purchase rights under the employee stock purchase plan. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including the option's expected term and the price volatility of the underlying stock. Equity instruments issued to nonemployees are recorded in the same manner as similar instruments issued to employees. Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may three six June 30, 2020 2019, Net Loss per Share The Company's basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share since dilutive common shares are not The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive: Six Months Ended June 30, 2020 2019 Series B convertible preferred stock 22,016,179 (a) - Warrants to purchase common stock 23,583,290 6,408 Stock options to purchase common stock 10,023,441 53,092 Restricted common stock awards 2,348 3,916 (a) As of June 30, 2020, 33,685 22,016,179 1 653.59 $1,000 $1.53 not Recently Issued and Adopted Accounting Standards In November 2019, 2019 08, 718 606 718. December 15, 2019, January 1, 2020 not In December 2019, 2019 12, 740 December 15, 2020, January 1, 2021 not not no We have reviewed other recent accounting pronouncements and concluded they are either not no |
Note 3 - Fair Value Measurement
Note 3 - Fair Value Measurements | 6 Months Ended |
Jun. 30, 2020 | |
Notes to Financial Statements | |
Fair Value Disclosures [Text Block] | 3. Fair Value Measurements The Company recognizes and discloses the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 3 Level 1 Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. Therefore, determining fair value for Level 1 not not Level 2 Pricing is provided by third not Level 3 Inputs used to measure fair value are unobservable inputs that are supported by little or no 3 Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. There were no June 30, 2020 December 31, 2019. The carrying amounts of the Company's financial assets and liabilities, including cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses as of June 30, 2020, December 31, 2019 There were no |
Note 4 - Investment in Limited
Note 4 - Investment in Limited Liability Company | 6 Months Ended |
Jun. 30, 2020 | |
Notes to Financial Statements | |
Equity Method Investments and Joint Ventures Disclosure [Text Block] | 4. Investment in Limited Liability Company On August 8, 2017, Under the terms of the Distributorship Agreement, ICM agreed to not third not three June 30, 2020 2019, 120 0 $10,000 0 six June 30, 2020 2019, 240 300 $20,000 $27,000, June 30, 2020, 5,040 $10,000 zero three June 30, 2020 2019, $20,000 $27,000 six June 30, 2020 2019, no June 30, 2020 December 31, 2019. In connection with the Distributorship Agreement, the Company also entered into a Membership Unit Subscription Agreement with ICM and the associated limited liability company operating agreement of ICM, pursuant to which the Company invested $2,500,000 not June 30, 2020, 7% three three June 30, 2020 2019, $86,000 $138,000, six June 30, 2020 2019, $268,000 $263,000, In February 2019, no |
Note 5 - Accrued Liabilities
Note 5 - Accrued Liabilities | 6 Months Ended |
Jun. 30, 2020 | |
Notes to Financial Statements | |
Accounts Payable and Accrued Liabilities Disclosure [Text Block] | 5. Accrued Liabilities Accrued liabilities consisted of the following as of June 30, 2020 December 31, 2019 ( June 30, December 31, 2020 2019 Deferred revenue - subscription rental program $ 804 $ 662 Accrued payroll and other related expenses 541 839 Accrued bonuses 380 726 Accrued professional fees 277 592 Current operating lease liabilities 265 268 Customer advances 241 53 Accrued sales commission 56 281 Customer contracts liabilities 21 108 Accrued inventory - 474 Accrued interest 3 440 Other accruals 247 255 Total accrued liabilities $ 2,835 $ 4,698 |
Note 6 - Note Payable
Note 6 - Note Payable | 6 Months Ended |
Jun. 30, 2020 | |
Notes to Financial Statements | |
Debt Disclosure [Text Block] | 6. Note Payable On May 22, 2017, December 12, 2017 November 29,2018 “2017 $20,000,000 $10,000,000 $30,000,000 December 29, 2017, $10,000,000 In connection with the 2017 two 10 2,220 $950.00 11 Under the 2017 November 12, 2019 six four 2017 12.5%, 4.0% may, three six June 30, 31, 2019, $324,000 $624,000, 5.0% As security for its obligations under the 2017 The terms of the 2017 2017 On November 12, 2019, 2017 No. 3” $28,981,000 $31,300,000. 31,300 9,893,776 5 120% $1.53 $1.836 11 one The Amendment No. 3 2017 ● repayment provisions were amended such that repayment is permitted only with, or after, the redemption in full of the Series B convertible preferred stock issued to CRG; ● the interest only payment period and the period during which the Company may 23rd first no 2017 ● modified certain of the covenants, including (i) to permit issuance of the Series B convertible preferred stock and any preferred stock issued in the equity financing and the exercise and performance by the Company of its rights and obligations in connection with such CRG preferred stock and any preferred stock issued in the equity financing, (ii) eliminate the Company's ability to enter into permitted acquisitions, (iii) further restrict the incurrence of additional indebtedness and removal of the equity cure right, and (iv) eliminate the minimum revenue requirement; and ● the back-end facility fee on the aggregate remaining principal balance on the term loan shall be increased from 5% 25%. During the three six June 30, 2020, $130,000 $256,000, As of June 30, 2020, As of June 30, 2020 December 31, 2019, $4,241,000 $3,983,000, The Company accounted for the changes in the 2017 31,300 9,893,776 November 26, 2019 $1,023.23 $32,027,000 10 $3,502,000 11 $6,705,000, December 31, 2019. As of June 30, 2020, Year Ending December 31, 2020 (remaining 6 months) $ - 2021 - 2022 - 2023 5,992 Total payments 5,992 Less: Amount representing interest (1,741 ) Present value of obligations 4,251 Less: Unamortized debt discount (10 ) Note payable, noncurrent portion $ 4,241 |
Note 7 - Paycheck Protection Pr
Note 7 - Paycheck Protection Program Loan | 6 Months Ended |
Jun. 30, 2020 | |
Notes to Financial Statements | |
Long-term Debt [Text Block] | 7. Paycheck Protection Program Loan The Paycheck Protection Program (“PPP”) was established under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) and is administered by the U.S. Small Business Administration. On April 24, 2020, $1,343,000 1.00% two seven may No As of June 30, 2020, Year Ending December 31, 2020 (remaining 6 months) $ 143 2021 860 2022 358 2023 - Total payments 1,361 Less: Amount representing interest (18 ) Present value of obligations 1,343 Paycheck Protection Program loan,current portion 559 Paycheck Protection Program loan, noncurrent portion $ 784 |
Note 8 - Leases
Note 8 - Leases | 6 Months Ended |
Jun. 30, 2020 | |
Notes to Financial Statements | |
Lessee, Operating Leases [Text Block] | 8 . Leases Lessee: The following information pertains to those operating lease agreements where the Company is the lessee. On February 1, 2017, 12,400 January 26, 2017. June 1, 2017 May 2021. June 2017. The monthly base rent under the Sublease is equal to $20.50 first $21.12 $21.75 second third $22,000. $88,000 In September 2018, 36 September 20, 2018. $3,000. After the adoption of ASU 842 January 1, 2019, 12 not The following table reflects the Company's lease assets and lease liabilities at June 30, 2020 December 31, 2019 ( June 30, December 31, 2020 2019 Assets: Operating lease right-of-use assets $ 267 $ 395 Liabilities: Current operating lease liabilities $ 265 $ 268 Noncurrent operating lease liabilities 7 132 $ 272 $ 400 The operating lease right-of-use assets are included in other assets on the condensed consolidated balance sheet. The operating lease liabilities are included in accrued liabilities and other noncurrent liabilities on the condensed consolidated balance sheet. The operating leases expense for the three June 30, 2020 2019 $73,000 $75,000, six June 30, 2020 2019 $149,000 $150,000, As of June 30, 2020, Year Ending December 31, 2020 (remaining 6 months) $ 153 2021 137 Total lease payments 290 Less: Amount representing interest (18 ) Present value of lease liabilities $ 272 The weighted average remaining lease term was approximately 11 June 30, 2020. three June 30, 2020 12.5%. Lessor: The following information pertains to those operating lease agreements where the Company is the lessor. As of June 30, 2020, Year Ending December 31, 2020 (remaining 6 months) $ 698 2021 106 Thereafter - Total $ 804 As of June 30, 2020, $1,087,000 three six June 30, 2020 $115,000 $228,000, |
Note 9 - Commitments and Contin
Note 9 - Commitments and Contingencies | 6 Months Ended |
Jun. 30, 2020 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | 9 . Commitments and Contingencies Indemnification Agreements The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with performance of services within the scope of the agreement, breach of the agreement by the Company, or noncompliance of regulations or laws by the Company, in all cases provided the indemnified party has not not not Loss Contingencies The Company is or has been subject to proceedings, lawsuits and other claims arising in the ordinary course of business. The Company evaluates contingent liabilities, including threatened or pending litigation, for potential losses. If the potential loss from any claim or legal proceeding is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Because of uncertainties related to these matters, accruals are based upon the best information available. For potential losses for which there is a reasonable possibility (meaning the likelihood is more than remote but less than probable) that a loss exists, the Company will disclose an estimate of the potential loss or range of such potential loss or include a statement that an estimate of the potential loss cannot be made. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation and may not |
Note 10 - Preferred Stock
Note 10 - Preferred Stock | 6 Months Ended |
Jun. 30, 2020 | |
Notes to Financial Statements | |
Preferred Stock [Text Block] | 10 . Preferred Stock In connection with the closing of the public offering in November 2019, With certain exceptions, as described in the Series A Certificate of Designation, the shares of Series A preferred stock have no Each share of Series A convertible preferred stock is convertible at any time at the holder's option into one The activity related to Series A convertible preferred stock during the six June 30, 2020 ● In January 2020, 1,183,151 ● In February 2020, 669,022 As of June 30, 2020, no As previously reported (see Note 6 31,300 9,893,776 November 26, 2019, 12.5% December 31, 2019, 378 $2,000 three June 30, 2020, 1,018 $3,000 six June 30, 2020, 2,007 $4,000 June 30, 2020, 33,685 no The Series B convertible preferred stock provides that for so long as any shares are outstanding, the consent of the holders of the Series B convertible preferred stockholders would be required to amend the Company's organizational documents, approve any merger, sale of assets, or other major corporate transaction, or incur additional indebtedness, among other items. The fair value of the Series B convertible preferred stock was determined in connection with the CRG debt conversion as part of the accounting for that transaction as a troubled debt restructuring. Based on our valuation analysis, as of November 26, 2019, $1,023.23 $32,027,000 31,300 6 Under the terms of the Series B Preferred Stock and Warrant Purchase Agreement, as amended, CRG will not |
Note 11 - Common Stock
Note 11 - Common Stock | 6 Months Ended |
Jun. 30, 2020 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | 1 1 . Common Stock Purchase Agreement with Lincoln Park Capital, LLC On June 8, 2020, $10,000,000 30 On June 9, 2020, 525,000 $0.65 may 250,000 may 300,000 not $1.00 may 500,000 not $2.00 may not $1,000,000. no In addition to Regular Purchases described above, the Company may not three 3 30% 95% Under certain circumstances and in accordance with the Purchase Agreement, the Company may Other than as described above, there are no Transaction costs in connection with the Purchase Agreement with LPC totaled approximately $452,000. $325,000. no 2019 In November 2019, “November 2019 $11,500,000, $9,922,000. The offering comprised of: ( 1 $1.55 one one $1.55 first one $1.55 fifth 2 $1.55 one one one $1.55 first one $1.55 fifth The securities comprising the units were immediately separable and were issued separately. A total of 1,945,943 5,473,410 7,419,353 7,419,353 As of June 30, 2020, no 10 As of June 30, 2020, 1,540,829 7,080,390 Warrants for Common Stock Restricted Common Shares The activity of restricted common shares for the six June 30, 2020 ● In June 2020, 34,531 $25,000. ● In March 2020, 28,313 $24,000. Warrants for Common Stock As of June 30, 2020, Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants February 2015 Common Shares February 17, 2025 $ 400.00 754 March 2015 Common Shares March 26, 2025 $ 272.00 14 May 2015 Common Shares May 12, 2025 $ 424.00 362 December 2015 Common Shares December 16, 2025 $ 560.00 267 April 2016 Common Shares April 1, 2026 $ 608.00 250 May 2016 Common Shares May 11, 2021 $ 774.00 50 June 2016 Common Shares June 20, 2026 $ 498.00 1,004 May 2017 Common Shares May 25, 2027 $ 950.00 2,220 November 2019 Common Shares November 26, 2020 $ 0.61 1,540,829 November 2019 Common Shares November 26, 2024 $ 0.61 7,080,390 November 2019 Common Shares November 26, 2024 $ 1.836 9,893,776 April 2020 Common Shares April 21, 2025 $ 0.6371 5,063,374 23,583,290 In connection with the November 2019 7,419,353 7,419,353 one $1.55 first one $1.55 fifth one one $1.55 one five $1.55 In February 2020, 1,026,240 $1,591,000. February 2020, 45,473 $70,000. On April 15, 2020, $1.55 $0.61 $0.61 $1.55 April 15, 2020, 718, 718 $1,838,000 Immediately Immediately before Modification After Modification Exercise price $1.55 $0.61 Common stock price $0.63 $0.63 Expected term (in years) 2.8 2.8 Average volatility 97% 97% Risk-free interest rate 0.27% 0.27% Dividend yield 0% 0% On April 16, 2020, 4,820,584 242,790 $3,089,000. In conjunction, the Company also agreed to issue new Series A- 2 4,820,584 2 242,790 $0.6371 five 2 2 $1,838,000 0%, 84.1%, 0.35% five 2 2 April 20, 2020. 2020 $326,000. In May 2020, 4,099 $2,500. In June 2020, 27,601 $17,000. June 2020, 50,700 $31,000. As of June 30, 2020, 1,540,829 7,080,390 In connection with the CRG Debt Conversion, CRG received warrants exercisable for 9,893,776 15% November 2019 five 120% $1.53 $1.836 $3,502,000 0%, 68.8%, 1.58% five In connection with the 2017 2,220, $950.00 ten $940,000 $790,000, three six June 30, 2020, $1,000 $2,000, three six June 30, 2019, $119,000 $202,000, June 30, 2020, $10,000. No three six June 30, 2020 2019. A total of 215 three six June 30, 2020. No three six June 30, 2019. |
Note 12 - Summary of Stock Opti
Note 12 - Summary of Stock Options | 6 Months Ended |
Jun. 30, 2020 | |
Notes to Financial Statements | |
Share-based Payment Arrangement [Text Block] | 1 2 . Summary of Stock Options Stock Option Plans The Company has issued equity awards in the form of stock options and restricted stock awards (“RSAs”) from two 2006 “2006 2013 “2013 As of June 30, 2020, 2006 104 no $992.00 2.6 As of June 30, 2020, 2013 10,023,337 4,502,522 $1.97 9.4 In January 2020, 2020 2013 2,639,926 11,872,531 14,512,457 January 1, 2020. Activity under the 2006 2013 Six Months Ended June 30, 2020 Weighted Weighted Average Number Average Remaining Aggregate of Exercise Contractual Intrinsic Shares Price Term (years) Value Options outstanding, beginning of period 10,087,678 $ 2.22 9.9 $ 3,928,715 Options granted 468,000 $ 0.88 Options exercised - Options canceled (532,237 ) $ 5.81 Options outstanding, end of period 10,023,441 $ 1.97 9.4 $ - Vested and exercisable and expected to vest, end of period 9,164,577 $ 2.06 9.4 $ - Vested and exercisable, end of period 1,447,596 $ 6.41 9.1 $ - The aggregate intrinsic value reflects the difference between the exercise price of the underlying stock options and the Company's closing share price as of June 30, 2020. The options outstanding and exercisable as of June 30, 2020 Weighted Number Weighted Average Number Weighted Outstanding Average Remaining Exercisable Average Range of as of Exercise Contractual as of Exercise Exercise Prices June 30, 2020 Price Term (Years) June 30, 2020 Price $0.69 - $0.89 9,830,708 $ 0.86 9.4 1,410,939 $ 0.87 $1.09 - $1.36 155,000 $ 1.26 9.7 12,500 $ 1.36 $38.00 - $58.00 1,250 $ 55.20 8.9 1,103 $ 57.17 $100.00 - $197.00 20,289 $ 141.91 8.4 10,650 $ 146.21 $202.00 - $283.00 725 $ 250.69 7.5 412 $ 253.75 $311.00 - $382.00 2,134 $ 344.37 7.1 1,511 $ 347.00 $430.00 - $497.00 6,687 $ 454.20 7.0 4,652 $ 455.41 $501.00 - $567.00 3,215 $ 537.49 6.9 2,610 $ 536.64 $600.00 - $661.00 1,392 $ 602.19 5.5 1,378 $ 601.59 $700.00 - $792.00 1,937 $ 767.72 6.3 1,737 $ 767.32 $992.00 - $992.00 104 $ 992.00 2.6 104 $ 992.00 Total: 10,023,441 $ 1.97 9.4 1,447,596 $ 6.41 Restricted Stock Awards During the three six June 30, 2020, no 2013 In June 2020, 250 June 2018. In July 2019, 378 2013 $38.08 378 In June 2019, 250 June 2018. In April 2019, 525 2013 $91.00 525 In January 2019, 3,625 2013 2018 2018 50% 50% six June 30, 2020, 22 June 30, 2020, zero As of June 30, 2020, 2,348 2017 The activity of the Company's 2017 six June 30, 2020 The eleventh 2017 “2017 April 1, 2020 June 30, 2020, 300 June 30, 2020 $0.48. The tenth 2017 January 1, 2020 March 31, 2020, 320 March 31, 2020 $0.59. As of June 30, 2020, 2017 472 The Company estimates the fair value of purchase rights under the ESPP using a Black-Scholes valuation model. The fair value of each purchase right was estimated on the date of grant using the Black-Scholes option valuation model and the straight-line attribution approach with the following weighted-average assumptions: Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Expected term (in years) 0.25 0.25 0.25 0.25 Average volatility 110% 87% 117% 81% Risk-free interest rate 0.09% 2.43% 0.84% 2.44% Dividend yield 0% 0% 0% 0% The weighted average grant date fair value of the purchase rights issued under the 2017 three six June 2020, $0.23 $0.33, 2017 three six June 30, 2019 $0.95 $0.68, Stock-Based Compensation There were no three June 30, 2020. six June 30, 2020, 468,000 $0.52 three six June 30, 2019, 1,900 23,350 $32.77 $71.77 no three six June 30, 2020 2019. The Company estimated the fair value of stock options using the Black-Scholes option pricing model. The fair value of employee and nonemployee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options granted was estimated using the following weighted average assumptions: Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Expected term (in years) N/A 5 5 5 Average volatility N/A 75% 73% 73% Risk-free interest rate N/A 2.03% 0.45% 2.49% Dividend yield N/A 0% 0% 0% Option-pricing models require the input of various subjective assumptions, including the option's expected life and the price volatility of the underlying stock. The expected stock price volatility is based on analysis of the Company's stock price history over a period commensurate with the expected term of the options, trading volume of comparable companies' stock, look-back volatilities and the Company specific events that affected volatility in a prior period. The expected term of employee stock options represents the weighted average period the stock options are expected to remain outstanding and is based on the history of exercises and cancellations on all past option grants made by the Company, the contractual term, the vesting period and the expected remaining term of the outstanding options. The risk-free interest rate is based on the U.S. Treasury interest rates whose term is consistent with the expected life of the stock options. No not not The following table shows stock-based compensation expense included in the condensed consolidated statements of operations for the three six June 30, 2020 2019 Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Cost of revenue $ 61 $ 34 $ 121 $ 66 Research and development 85 53 171 93 Selling, general and administrative 512 534 1,075 958 Total $ 658 $ 621 $ 1,367 $ 1,117 As of June 30, 2020, $5,819,000. 2.9 |
Note 13 - Income Taxes
Note 13 - Income Taxes | 6 Months Ended |
Jun. 30, 2020 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | 1 3 . Income Taxes No no For interim periods, the Company estimates its annual effective income tax rate and applies the estimated rate to the year-to-date income or loss before income taxes. The Company also computes the tax provision or benefit related to items reported separately and recognizes the items net of their related tax effect in the interim periods in which they occur. The Company also recognizes the effect of changes in enacted tax laws or rates in the interim periods in which the changes occur. The Company's effective tax rate is 0% three six June 30, 2020. 2020 0%. The Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted on March 27, 2020 |
Note 14 - Related Party Transac
Note 14 - Related Party Transactions | 6 Months Ended |
Jun. 30, 2020 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | 1 4 . Related Party Transactions In June 2006, October 4, 2007. 300 June 30, 2020, 855 375 $467,000 $1,820,000 three June 30, 2020 2019, $749,000 $3,132,000 six June 2020 2019 June 30, 2020 December 31, 2019 $165,000 $124,000, In August 2017, February 2019, no |
Note 15 - Restructuring Costs
Note 15 - Restructuring Costs | 6 Months Ended |
Jun. 30, 2020 | |
Notes to Financial Statements | |
Restructuring and Related Activities Disclosure [Text Block] | 1 5 . Restructuring Costs In January 2019, 40 $742,000 first 2019 |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 6 Months Ended |
Jun. 30, 2020 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Financial Statement Presentation The condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation. |
Reserve Stock Split, Policy [Policy Text Block] | Reverse Stock Split The Company effected a 1 100 September 18, 2019. not No $6,000. The par value of the Company's common stock remained unchanged at $0.0001 The number of authorized shares of common stock remained at 75,000,000. The reverse stock split proportionately affected the number of shares of common stock available for issuance under the Company's equity incentive plans. All stock options, warrants and restricted stock awards of the Company outstanding shares immediately prior to the reverse stock split were adjusted in accordance with their terms. On the effective date of the reverse stock split, (i) each 100 one 100 1 1 100 100 1 All of the share numbers, share prices, and exercise prices have been adjusted, on a retroactive basis, to reflect this 1 100 |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three one may, |
Concentration Risk, Credit Risk, Policy [Policy Text Block] | Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no Most of the Company's products to date require clearance or approvals from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commencing commercial sales. There can be no The Company is subject to risks common to companies in the medical device industry including, but not The Company designs, develops, manufactures and markets a medical device that it refers to as the Viveve System, which is intended for the non-invasive treatment of vaginal introital laxity, for improved sexual function, for vaginal rejuvenation, for use in general surgical procedures for electrocoagulation and hemostasis, and stress urinary incontinence, depending on the relevant country-specific clearance or approval. The Viveve System consists of three four five third In North America, the Company sells its products primarily through a direct sales force to health care practitioners. Outside North America, the Company sells through an extensive network of distribution partners. During the three June 30, 2020, three 74% three June 30, 2019, three 55% six June 30, 2020, one 49% six June 30, 2019, two 32% There were no 10% three six June 30, 2020 2019. As of June 30, 2020, one 21% December 31, 2019, two 49% |
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block] | Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and are not six may six not $463,000 June 30, 2020 $407,000 December 31, 2019. During the three six June 30, 2020, $173,000 no three six June 30, 2019. |
Revenue from Contract with Customer [Policy Text Block] | Revenue from Contracts with Customers Revenue consists primarily of the sale of the Viveve System, single-use treatment tips and ancillary consumables. The Company applies the following five 1 2 3 4 5 Rental revenue is generated through the lease of the Viveve System. The Company's operating leases for the Viveve System generally have a rental period of six nine June 30, 2019 not June 30, 2020 December 31, 2019, $804,000 $662,000, three six June 30, 2020, $6,000 $303,000, December 31, 2019. Late in the first 2020, 19 70 80% three 19 In connection with the lease of the Viveve System, the Company offers single-use treatment tips and ancillary consumables that are considered non-lease components. In the contracts with lease and non-lease components, the Company follows the relevant guidance in ASC 606, Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance for differing indications, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Latin America, Europe, the Middle East and Asia Pacific. In North America, we market and sell primarily through a direct sales force. Outside of North America, we market and sell primarily through distribution partners. The Company does not Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer advance payment from accrued liabilities when revenue is recognized upon shipment of the products. Contract Assets and Liabilities The Company continually evaluates whether the revenue generating activities and advanced payment arrangements with customers result in the recognition of contract assets or liabilities. No June 30, 2020 December 31, 2019. $21,000 $108,000, not June 30, 2020 December 31, 2019, three six June 30, 2020, $4,000 $87,000, December 31, 2019. The following table reflects the changes in our customer contract liabilities for the six June 30, 2020: June 30, December 31, 2020 2019 Change Customer contracts liabilities: Marketing programs $ 21 $ 108 $ (87 ) Total $ 21 $ 108 $ (87 ) Separately, accounts receivable, net represents receivables from contracts with customers. Significant Financing Component The Company applies the practical expedient to not not one three six June 30, 2020 2019, not Contract Costs The Company expects that commissions paid to obtain subscriptions are recoverable and has therefore capitalized them as a contract costs in the amount of $102,000 $337,000 June 30, 2020 December 31, 2019, June 30, 2019 no three June 30, 2019. three June 30, 2020 2019, $133,000 zero, six June 30, 2020 2019, $331,000 zero no one Shipping and Handling Shipping costs billed to customers are recorded as revenue. Shipping and handling expense related to costs incurred to deliver product are recognized within cost of goods sold. The Company accounts for shipping and handling activities that occur after control has transferred as a fulfillment cost as opposed to a separate performance obligation, and the costs of shipping and handling are recognized concurrently with the related revenue. Revenue by Geographic Area Management has determined that the sales by geography is a key indicator for understanding the Company's financials because of the different sales and business models that are required in the various regions of the world (including regulatory, selling channels, pricing, customers and marketing efforts). The following table presents the revenue from unaffiliated customers disaggregated by geographic area for the three six June 30, 2020 2019 Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 North America $ 116 $ 663 $ 804 $ 2,455 Asia Pacific 588 343 1,185 1,310 Europe and Middle East - 43 5 289 Latin America - 3 14 10 Total $ 704 $ 1,052 $ 2,008 $ 4,064 The Company determines geographic location of its revenue based upon the destination of the shipments of its products. |
Equity Method Investments [Policy Text Block] | Investments in Unconsolidated Affiliates The Company uses the equity method to account for its investments in entities that it does not 1 2 3 three not The Company assesses the potential impairment of the equity method investments when indicators such as a history of operating losses, a negative earnings and cash flow outlook, and the financial condition and prospects for the investee's business segment might indicate a loss in value. The carrying value of the investments is reviewed annually for changes in circumstances or the occurrence of events that suggest the investment may not No three six June 30 , 2020 2019. |
Standard Product Warranty, Policy [Policy Text Block] | Product Warranty The Company's products sold to customers are generally subject to warranties between one three not |
Share-based Payment Arrangement [Policy Text Block] | Accounting for Stock-Based Compensation Share-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the employee's service period. The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award. The Company determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair value for stock options and purchase rights under the employee stock purchase plan. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including the option's expected term and the price volatility of the underlying stock. Equity instruments issued to nonemployees are recorded in the same manner as similar instruments issued to employees. |
Comprehensive Income, Policy [Policy Text Block] | Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may three six June 30, 2020 2019, |
Earnings Per Share, Policy [Policy Text Block] | Net Loss per Share The Company's basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share since dilutive common shares are not The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive: Six Months Ended June 30, 2020 2019 Series B convertible preferred stock 22,016,179 (a) - Warrants to purchase common stock 23,583,290 6,408 Stock options to purchase common stock 10,023,441 53,092 Restricted common stock awards 2,348 3,916 (a) As of June 30, 2020, 33,685 22,016,179 1 653.59 $1,000 $1.53 not |
New Accounting Pronouncements, Policy [Policy Text Block] | Recently Issued and Adopted Accounting Standards In November 2019, 2019 08, 718 606 718. December 15, 2019, January 1, 2020 not In December 2019, 2019 12, 740 December 15, 2020, January 1, 2021 not not no We have reviewed other recent accounting pronouncements and concluded they are either not no |
Note 2 - Summary of Significa_2
Note 2 - Summary of Significant Accounting Policies (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Notes Tables | |
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] | June 30, December 31, 2020 2019 Change Customer contracts liabilities: Marketing programs $ 21 $ 108 $ (87 ) Total $ 21 $ 108 $ (87 ) |
Revenue from External Customers by Geographic Areas [Table Text Block] | Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 North America $ 116 $ 663 $ 804 $ 2,455 Asia Pacific 588 343 1,185 1,310 Europe and Middle East - 43 5 289 Latin America - 3 14 10 Total $ 704 $ 1,052 $ 2,008 $ 4,064 |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | Six Months Ended June 30, 2020 2019 Series B convertible preferred stock 22,016,179 (a) - Warrants to purchase common stock 23,583,290 6,408 Stock options to purchase common stock 10,023,441 53,092 Restricted common stock awards 2,348 3,916 |
Note 5 - Accrued Liabilities (T
Note 5 - Accrued Liabilities (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Notes Tables | |
Schedule of Accrued Liabilities [Table Text Block] | June 30, December 31, 2020 2019 Deferred revenue - subscription rental program $ 804 $ 662 Accrued payroll and other related expenses 541 839 Accrued bonuses 380 726 Accrued professional fees 277 592 Current operating lease liabilities 265 268 Customer advances 241 53 Accrued sales commission 56 281 Customer contracts liabilities 21 108 Accrued inventory - 474 Accrued interest 3 440 Other accruals 247 255 Total accrued liabilities $ 2,835 $ 4,698 |
Note 6 - Note Payable (Tables)
Note 6 - Note Payable (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
The 2017 Loan Agreement [Member] | |
Notes Tables | |
Schedule of Debt [Table Text Block] | Year Ending December 31, 2020 (remaining 6 months) $ - 2021 - 2022 - 2023 5,992 Total payments 5,992 Less: Amount representing interest (1,741 ) Present value of obligations 4,251 Less: Unamortized debt discount (10 ) Note payable, noncurrent portion $ 4,241 |
Note 7 - Paycheck Protection _2
Note 7 - Paycheck Protection Program Loan (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Notes Tables | |
Schedule of Maturities of Long-term Debt [Table Text Block] | Year Ending December 31, 2020 (remaining 6 months) $ 143 2021 860 2022 358 2023 - Total payments 1,361 Less: Amount representing interest (18 ) Present value of obligations 1,343 Paycheck Protection Program loan,current portion 559 Paycheck Protection Program loan, noncurrent portion $ 784 |
Note 8 - Leases (Tables)
Note 8 - Leases (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Notes Tables | |
Lessee, Lease Assets and Liabilities [Table Text Block] | June 30, December 31, 2020 2019 Assets: Operating lease right-of-use assets $ 267 $ 395 Liabilities: Current operating lease liabilities $ 265 $ 268 Noncurrent operating lease liabilities 7 132 $ 272 $ 400 |
Lessee, Operating Lease, Liability, Maturity [Table Text Block] | Year Ending December 31, 2020 (remaining 6 months) $ 153 2021 137 Total lease payments 290 Less: Amount representing interest (18 ) Present value of lease liabilities $ 272 |
Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block] | Year Ending December 31, 2020 (remaining 6 months) $ 698 2021 106 Thereafter - Total $ 804 |
Note 11 - Common Stock (Tables)
Note 11 - Common Stock (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Notes Tables | |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants February 2015 Common Shares February 17, 2025 $ 400.00 754 March 2015 Common Shares March 26, 2025 $ 272.00 14 May 2015 Common Shares May 12, 2025 $ 424.00 362 December 2015 Common Shares December 16, 2025 $ 560.00 267 April 2016 Common Shares April 1, 2026 $ 608.00 250 May 2016 Common Shares May 11, 2021 $ 774.00 50 June 2016 Common Shares June 20, 2026 $ 498.00 1,004 May 2017 Common Shares May 25, 2027 $ 950.00 2,220 November 2019 Common Shares November 26, 2020 $ 0.61 1,540,829 November 2019 Common Shares November 26, 2024 $ 0.61 7,080,390 November 2019 Common Shares November 26, 2024 $ 1.836 9,893,776 April 2020 Common Shares April 21, 2025 $ 0.6371 5,063,374 23,583,290 |
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] | Immediately Immediately before Modification After Modification Exercise price $1.55 $0.61 Common stock price $0.63 $0.63 Expected term (in years) 2.8 2.8 Average volatility 97% 97% Risk-free interest rate 0.27% 0.27% Dividend yield 0% 0% |
Note 12 - Summary of Stock Op_2
Note 12 - Summary of Stock Options (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Notes Tables | |
Share-based Payment Arrangement, Option, Activity [Table Text Block] | Six Months Ended June 30, 2020 Weighted Weighted Average Number Average Remaining Aggregate of Exercise Contractual Intrinsic Shares Price Term (years) Value Options outstanding, beginning of period 10,087,678 $ 2.22 9.9 $ 3,928,715 Options granted 468,000 $ 0.88 Options exercised - Options canceled (532,237 ) $ 5.81 Options outstanding, end of period 10,023,441 $ 1.97 9.4 $ - Vested and exercisable and expected to vest, end of period 9,164,577 $ 2.06 9.4 $ - Vested and exercisable, end of period 1,447,596 $ 6.41 9.1 $ - |
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block] | Weighted Number Weighted Average Number Weighted Outstanding Average Remaining Exercisable Average Range of as of Exercise Contractual as of Exercise Exercise Prices June 30, 2020 Price Term (Years) June 30, 2020 Price $0.69 - $0.89 9,830,708 $ 0.86 9.4 1,410,939 $ 0.87 $1.09 - $1.36 155,000 $ 1.26 9.7 12,500 $ 1.36 $38.00 - $58.00 1,250 $ 55.20 8.9 1,103 $ 57.17 $100.00 - $197.00 20,289 $ 141.91 8.4 10,650 $ 146.21 $202.00 - $283.00 725 $ 250.69 7.5 412 $ 253.75 $311.00 - $382.00 2,134 $ 344.37 7.1 1,511 $ 347.00 $430.00 - $497.00 6,687 $ 454.20 7.0 4,652 $ 455.41 $501.00 - $567.00 3,215 $ 537.49 6.9 2,610 $ 536.64 $600.00 - $661.00 1,392 $ 602.19 5.5 1,378 $ 601.59 $700.00 - $792.00 1,937 $ 767.72 6.3 1,737 $ 767.32 $992.00 - $992.00 104 $ 992.00 2.6 104 $ 992.00 Total: 10,023,441 $ 1.97 9.4 1,447,596 $ 6.41 |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Expected term (in years) N/A 5 5 5 Average volatility N/A 75% 73% 73% Risk-free interest rate N/A 2.03% 0.45% 2.49% Dividend yield N/A 0% 0% 0% |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] | Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Cost of revenue $ 61 $ 34 $ 121 $ 66 Research and development 85 53 171 93 Selling, general and administrative 512 534 1,075 958 Total $ 658 $ 621 $ 1,367 $ 1,117 |
2017 Employee Stock Purchase Plan [Member] | |
Notes Tables | |
Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] | Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Expected term (in years) 0.25 0.25 0.25 0.25 Average volatility 110% 87% 117% 81% Risk-free interest rate 0.09% 2.43% 0.84% 2.44% Dividend yield 0% 0% 0% 0% |
Note 1 - The Company and Basi_2
Note 1 - The Company and Basis of Presentation (Details Textual) - USD ($) | Jun. 09, 2020 | Jun. 08, 2020 | Apr. 20, 2020 | Apr. 16, 2020 | Nov. 26, 2019 | Nov. 12, 2019 | Jun. 30, 2020 | May 31, 2020 | Feb. 29, 2020 | Nov. 30, 2019 | Jun. 30, 2020 | Mar. 31, 2020 | Jun. 30, 2020 | Jun. 30, 2019 | Nov. 30, 2019 | Apr. 15, 2020 | Dec. 31, 2019 | |
Proceeds from Warrant Exercises | $ 4,800,000 | |||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 23,583,290 | 23,583,290 | 23,583,290 | |||||||||||||||
Payments of Warrant Issuance Costs | $ 326,000 | $ 326,000 | ||||||||||||||||
Retained Earnings (Accumulated Deficit), Ending Balance | $ (211,336,000) | $ (211,336,000) | (211,336,000) | $ (197,911,000) | [1] | |||||||||||||
Cash and Cash Equivalents, at Carrying Value, Ending Balance | 8,500,000 | 8,500,000 | 8,500,000 | $ 13,308,000 | [1] | |||||||||||||
Working Capital | $ 11,704,000 | $ 11,704,000 | 11,704,000 | |||||||||||||||
Net Cash Provided by (Used in) Operating Activities, Total | $ (10,189,000) | $ (19,254,000) | ||||||||||||||||
Conversion of Term Loan with CRG Into Stock and Warrants [Member] | ||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 28,981,000 | |||||||||||||||||
Debt Conversion, Converted Instrument, Amount | $ 31,300,000 | |||||||||||||||||
Conversion of Term Loan with CRG Into Series B Convertible Preferred Stock [Member] | ||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in shares) | 31,300 | 31,300 | ||||||||||||||||
Series A Preferred Stock [Member] | ||||||||||||||||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | 0 | 0 | 0 | 1,852,173 | ||||||||||||||
Series A Convertible Preferred Stock [Member] | ||||||||||||||||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | 0 | 0 | 0 | |||||||||||||||
Common Stock [Member] | ||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 525,000 | |||||||||||||||||
Series A and Series B Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.61 | $ 1.55 | ||||||||||||||||
Proceeds from Warrant Exercises | $ 3,089,000 | |||||||||||||||||
Series A Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 1.55 | $ 1.55 | ||||||||||||||||
Stock Issued During Period, Shares, Warrant Exercises (in shares) | 4,820,584 | 27,601 | 4,099 | 1,026,240 | ||||||||||||||
Proceeds from Warrant Exercises | $ 17,000 | $ 2,500 | $ 1,591,000 | |||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 1,540,829 | 7,419,353 | 1,540,829 | 1,540,829 | 7,419,353 | |||||||||||||
Warrants and Rights Outstanding, Term (Year) | 1 year | 1 year | ||||||||||||||||
Series A Warrants [Member] | Common Stock [Member] | ||||||||||||||||||
Stock Issued During Period, Shares, Warrant Exercises (in shares) | 4,852,284 | 1,026,240 | ||||||||||||||||
Series B Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 1.55 | $ 1.55 | ||||||||||||||||
Stock Issued During Period, Shares, Warrant Exercises (in shares) | 242,790 | 50,700 | 45,473 | |||||||||||||||
Proceeds from Warrant Exercises | $ 31,000 | $ 70,000 | ||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 7,080,390 | 7,419,353 | 7,080,390 | 7,080,390 | 7,419,353 | |||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | 5 years | ||||||||||||||||
Series B Warrants [Member] | Common Stock [Member] | ||||||||||||||||||
Stock Issued During Period, Shares, Warrant Exercises (in shares) | 293,490 | 45,473 | ||||||||||||||||
Series A-2 Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 4,820,584 | |||||||||||||||||
Series B-2 Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 242,790 | |||||||||||||||||
Series A-2 and Series B-2 Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.6371 | |||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||||||||||||||
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 9,893,776 | 9,893,776 | ||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||||||||||||||
Purchase Agreement with LPC [Member] | ||||||||||||||||||
Maximum Amount of Shares Issuable | $ 10,000,000 | $ 10,000,000 | ||||||||||||||||
Stock Purchase Agreement Duration Period (Month) | 2 years 180 days | 2 years 180 days | ||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 525,000 | |||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 0.65 | |||||||||||||||||
Maximum Number of Shares Issuable on Any Business Day Selected by The Company (in shares) | 250,000 | |||||||||||||||||
Maximum Number of Shares Issuable on Any Business Day Selected by The Company in Certain Circumstances (in shares) | 500,000 | |||||||||||||||||
November 2019 Offering [Member] | ||||||||||||||||||
Proceeds from Issuance or Sale of Equity, Total | $ 11,500,000 | |||||||||||||||||
Proceeds From Issuance of Common Stock, Net | $ 9,922,000 | |||||||||||||||||
November 2019 Offering [Member] | Series A Preferred Stock [Member] | ||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 5,473,410 | |||||||||||||||||
November 2019 Offering [Member] | Common Stock [Member] | ||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 1,945,943 | 1,945,943 | ||||||||||||||||
[1] | The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date. |
Note 2 - Summary of Significa_3
Note 2 - Summary of Significant Accounting Policies (Details Textual) | Sep. 18, 2019USD ($) | Jun. 30, 2020USD ($)$ / sharesshares | Jun. 30, 2019USD ($) | Mar. 31, 2019USD ($) | Jun. 30, 2020USD ($)$ / sharesshares | Jun. 30, 2019USD ($) | Dec. 31, 2019USD ($)$ / sharesshares | |
Payments for Fractional Shares of Reverse Stock Split | $ 6,000 | |||||||
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares | $ 0.0001 | $ 0.0001 | $ 0.0001 | [1] | ||||
Common Stock, Shares Authorized (in shares) | shares | 75,000,000 | 75,000,000 | 75,000,000 | [1] | ||||
Number of Financial Institutions | 1 | 1 | ||||||
Accounts Receivable, Allowance for Credit Loss, Ending Balance | $ 463,000 | $ 463,000 | $ 407,000 | |||||
Accounts Receivable, Allowance for Credit Loss, Writeoff | 173,000 | $ 0 | 173,000 | $ 0 | ||||
Deferred Income | 804,000 | 804,000 | 662,000 | |||||
Contract with Customer, Liability, Revenue Recognized | 6,000 | 303,000 | ||||||
Contract with Customer, Asset, after Allowance for Credit Loss, Total | 0 | 0 | 0 | |||||
Contract with Customer, Liability, Total | 21,000 | 21,000 | 108,000 | |||||
Capitalized Contract Cost, Net, Total | 102,000 | 102,000 | $ 337,000 | |||||
Capitalized Contract Cost, Impairment Loss | 0 | $ 0 | 0 | |||||
Capitalized Contract Cost, Amortization | 133,000 | 0 | 331,000 | 0 | ||||
Equity Method Investment, Other than Temporary Impairment | $ 0 | $ 0 | $ 0 | $ 0 | ||||
Series B Preferred Stock [Member] | ||||||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | shares | 33,685 | 33,685 | 31,678 | [1] | ||||
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | shares | 22,016,179 | 22,016,179 | ||||||
Conversion of Stock Exchange Ratio | 653.59 | |||||||
Preferred Stock, Liquidation Preference Per Share (in dollars per share) | $ / shares | $ 1,000 | $ 1,000 | ||||||
Conversion of Stock, Conversion Rate (in dollars per share) | $ / shares | $ 1.53 | $ 1.53 | ||||||
Minimum [Member] | ||||||||
Warranty Period (Year) | 1 year | |||||||
Maximum [Member] | ||||||||
Warranty Period (Year) | 3 years | |||||||
Marketing Programs [Member] | ||||||||
Contract with Customer, Liability, Revenue Recognized | $ 4,000 | $ 87,000 | ||||||
Contract with Customer, Liability, Total | $ 21,000 | $ 21,000 | $ 108,000 | |||||
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | ||||||||
Concentration Risk, Number of Customers | 3 | 3 | 1 | 2 | ||||
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Three Customers [Member] | ||||||||
Concentration Risk, Percentage | 74.00% | 55.00% | ||||||
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | One Customer [Member] | ||||||||
Concentration Risk, Percentage | 49.00% | |||||||
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Two Customers [Member] | ||||||||
Concentration Risk, Percentage | 32.00% | |||||||
Customer Concentration Risk [Member] | Accounts Receivable [Member] | ||||||||
Concentration Risk, Number of Customers | 1 | 2 | ||||||
Customer Concentration Risk [Member] | Accounts Receivable [Member] | One Customer [Member] | ||||||||
Concentration Risk, Percentage | 21.00% | |||||||
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Two Customers [Member] | ||||||||
Concentration Risk, Percentage | 49.00% | |||||||
Reverse Stock Split [Member] | ||||||||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 100 | |||||||
[1] | The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date. |
Note 2 - Summary of Significa_4
Note 2 - Summary of Significant Accounting Policies - Customer Contract Liabilities (Details) - USD ($) | 6 Months Ended | |
Jun. 30, 2020 | Dec. 31, 2019 | |
Customer contract liabilities | $ 21,000 | $ 108,000 |
Change in customer contract liabilities | (87,000) | |
Marketing Programs [Member] | ||
Customer contract liabilities | 21,000 | $ 108,000 |
Change in customer contract liabilities | $ (87,000) |
Note 2 - Summary of Significa_5
Note 2 - Summary of Significant Accounting Policies - Revenue From Unaffiliated Customers by Geographic Area (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | |
Revenue | $ 704 | $ 1,052 | $ 2,008 | $ 4,064 |
North America [Member] | ||||
Revenue | 116 | 663 | 804 | 2,455 |
Asia Pacific [Member] | ||||
Revenue | 588 | 343 | 1,185 | 1,310 |
Europe And Middle East [Member] | ||||
Revenue | 43 | 5 | 289 | |
Latin America [Member] | ||||
Revenue | $ 3 | $ 14 | $ 10 |
Note 2 - Summary of Significa_6
Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | ||
Series B Convertible Preferred Stock [Member] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares) | 22,016,179 | [1] | |
Common Stock Warrants [Member] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares) | 23,583,290 | 6,408 | |
Share-based Payment Arrangement, Option [Member] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares) | 10,023,441 | 53,092 | |
Restricted Stock [Member] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares) | 2,348 | 3,916 | |
[1] | As of June 30, 2020, a total of 33,685 shares of Series B convertible preferred stock were outstanding and are convertible into 22,016,179 shares of common stock. Each share of Series B preferred stock is convertible at the holder's option into shares of common stock at a conversion ratio of 1-for-653.59 per share determined by dividing the Series B liquidation amount of $1,000 per share by the Series B conversion price of $1.53 per share. However, under the terms of the Series B Preferred Stock and Warrant Purchase Agreement, as amended, CRG will not convert the Series B preferred stock or exercise the CRG warrants until the Company's stockholders act to authorize additional number of shares of common stock sufficient to cover the conversion shares. |
Note 4 - Investment in Limite_2
Note 4 - Investment in Limited Liability Company (Details Textual) | Aug. 08, 2017USD ($) | Jun. 30, 2020USD ($) | Jun. 30, 2019USD ($) | Jun. 30, 2020USD ($) | Jun. 30, 2019USD ($) | Jun. 30, 2020USD ($) |
Income (Loss) from Equity Method Investments, Total | $ (86,000) | $ (138,000) | $ (268,000) | $ (263,000) | ||
InControl Medical [Member] | ||||||
Equity Method Investment, Ownership Percentage | 7.00% | 7.00% | 7.00% | |||
Income (Loss) from Equity Method Investments, Total | $ 86,000 | $ 138,000 | $ 268,000 | $ 263,000 | ||
InControl Medical [Member] | Membership Unit Subscription Agreement [Member] | ||||||
Unrecorded Unconditional Purchase Obligation, Period Quantity Purchased | 120 | 0 | 240 | 300 | 5,040 | |
Unrecorded Unconditional Purchase Obligation, Purchases | $ 10,000 | $ 0 | $ 20,000 | $ 27,000 | ||
Payments for Purchase of Products | 10,000 | $ 0 | 20,000 | $ 27,000 | ||
Accounts Payable, Related Parties, Current | $ 0 | $ 0 | $ 0 | |||
Payments to Acquire Equity Method Investments | $ 2,500,000 |
Note 5 - Accrued Liabilities -
Note 5 - Accrued Liabilities - Accrued Liabilities (Details) - USD ($) $ in Thousands | Jun. 30, 2020 | Dec. 31, 2019 | |
Deferred revenue - subscription rental program | $ 804 | $ 662 | |
Accrued payroll and other related expenses | 541 | 839 | |
Accrued bonuses | 380 | 726 | |
Accrued professional fees | 277 | 592 | |
Accrued sales commission | 56 | 281 | |
Accrued inventory | 474 | ||
Accrued interest | 3 | 440 | |
Other accruals | 247 | 255 | |
Total accrued liabilities | 2,835 | 4,698 | [1] |
Customer Advances [Member] | |||
Contract with customer, liability | 241 | 53 | |
Customer Contracts Liabilites [Member] | |||
Contract with customer, liability | 21 | 108 | |
Accrued Liabilities [Member] | |||
Current operating lease liabilities | $ 265 | $ 268 | |
[1] | The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date. |
Note 6 - Note Payable (Details
Note 6 - Note Payable (Details Textual) - USD ($) | Nov. 26, 2019 | Nov. 12, 2019 | Dec. 29, 2017 | May 22, 2017 | Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | Dec. 31, 2019 | |
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 23,583,290 | 23,583,290 | ||||||||
Notes Payable, Noncurrent, Total | $ 4,241,000 | $ 4,241,000 | $ 3,983,000 | [1] | ||||||
Gains (Losses) on Restructuring of Debt | $ (6,705,000) | |||||||||
Series B Preferred Stock [Member] | ||||||||||
Conversion of Stock, Conversion Rate (in dollars per share) | $ 1.53 | $ 1.53 | ||||||||
Preferred Stock, Fair Value, Per Share (in dollars per share) | $ 1,023.23 | |||||||||
Convertible Preferred Stock, Fair Value | $ 32,027,000 | |||||||||
Minimum [Member] | Series B Convertible Preferred Stock Into Common Stock [Member] | ||||||||||
Conversion of Stock, Conversion Rate (in dollars per share) | $ 1.53 | |||||||||
Maximum [Member] | Series B Convertible Preferred Stock Into Common Stock [Member] | ||||||||||
Conversion of Stock, Conversion Rate (in dollars per share) | $ 1.836 | |||||||||
Conversion of Term Loan with CRG Into Stock and Warrants [Member] | ||||||||||
Debt Conversion, Original Debt, Amount | $ 28,981,000 | |||||||||
Debt Conversion, Converted Instrument, Amount | $ 31,300,000 | |||||||||
Conversion of Term Loan with CRG Into Series B Convertible Preferred Stock [Member] | ||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in shares) | 31,300 | 31,300 | ||||||||
May 2017 Issuance Related to 2017 Loan Agreement [Member] | ||||||||||
Warrants and Rights Outstanding, Term (Year) | 10 years | |||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 2,220 | |||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 950 | |||||||||
Warrants and Rights Outstanding | $ 940,000 | |||||||||
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | ||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 9,893,776 | 9,893,776 | ||||||||
Class of Warrants and Rights Outstanding, Exercise Price Percentage of Conversion Rate | 120.00% | |||||||||
Warrants and Rights Outstanding | $ 3,502,000 | $ 3,502,000 | $ 3,502,000 | |||||||
The 2017 Loan Agreement [Member] | ||||||||||
Notes Payable, Noncurrent, Total | 4,241,000 | 4,241,000 | ||||||||
The 2017 Loan Agreement [Member] | CRG LP [Member] | ||||||||||
Debt Instrument, Face Amount | 20,000,000 | |||||||||
Debt Agreement, Covenant, Additional Funding | 10,000,000 | |||||||||
Debt Agreement, Maximum Borrowing Capacity | $ 30,000,000 | |||||||||
Proceeds from Lines of Credit, Total | $ 10,000,000 | |||||||||
Debt Instrument, Term (Year) | 6 years | |||||||||
Debt instrument, Interest Only Payment, Period (Year) | 4 years | |||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.50% | |||||||||
Debt Instrument, Interest Rate, Stated Percentage Deferred During Interest-only Period | 4.00% | |||||||||
Paid-in-Kind Interest | 130,000 | $ 324,000 | 256,000 | $ 624,000 | ||||||
Debt Instrument, Prepayment Fee, Percentage | 5.00% | |||||||||
Debt Instrument, Back-end Facility Fee Percentage of Principal | 25.00% | 5.00% | ||||||||
Notes Payable, Noncurrent, Total | $ 4,241,000 | $ 4,241,000 | $ 3,983,000 | |||||||
[1] | The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date. |
Note 6 - Note Payable - Summary
Note 6 - Note Payable - Summary of Note Payable (Details) - USD ($) | Jun. 30, 2020 | Dec. 31, 2019 | [1] |
Less: Unamortized debt discount | $ (10,000) | ||
Note payable, noncurrent portion | 4,241,000 | $ 3,983,000 | |
The 2017 Loan Agreement [Member] | |||
2020 (remaining 6 months) | |||
2021 | |||
2022 | |||
2023 | 5,992,000 | ||
Total payments | 5,992,000 | ||
Less: Amount representing interest | (1,741,000) | ||
Present value of obligations | 4,251,000 | ||
Less: Unamortized debt discount | (10,000) | ||
Note payable, noncurrent portion | $ 4,241,000 | ||
[1] | The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date. |
Note 7 - Paycheck Protection _3
Note 7 - Paycheck Protection Program Loan (Details Textual) - USD ($) | Apr. 24, 2020 | Jun. 30, 2020 | Jun. 30, 2019 |
Proceeds from Issuance of Unsecured Debt | $ 1,343,000 | ||
Paycheck Protection Program CARES Act [Member] | |||
Proceeds from Issuance of Unsecured Debt | $ 1,343,000 |
Note 7 - Paycheck Protection _4
Note 7 - Paycheck Protection Program Loan - Summary of Paycheck Protection Program Loan (Details) - Paycheck Protection Program CARES Act [Member] $ in Thousands | Jun. 30, 2020USD ($) |
2020 (remaining 6 months) | $ 143 |
2021 | 860 |
2022 | 358 |
2023 | |
Total payments | 1,361 |
Less: Amount representing interest | (18) |
Present value of obligations | 1,343 |
Paycheck Protection Program loan,current portion | 559 |
Paycheck Protection Program loan, noncurrent portion | $ 784 |
Note 8 - Leases (Details Textua
Note 8 - Leases (Details Textual) | 1 Months Ended | 3 Months Ended | 6 Months Ended | |||||
Sep. 30, 2018USD ($) | Jun. 30, 2020USD ($) | Jun. 30, 2019USD ($) | Jun. 30, 2020USD ($) | Jun. 30, 2019USD ($) | Dec. 31, 2019USD ($) | [1] | Feb. 01, 2017USD ($)ft² | |
Operating Lease, Expense | $ 73,000 | $ 75,000 | $ 149,000 | $ 150,000 | ||||
Operating Lease, Weighted Average Remaining Lease Term (Month) | 330 days | 330 days | ||||||
Operating Lease, Weighted Average Discount Rate, Percent | 12.50% | 12.50% | ||||||
Property, Plant and Equipment, Net, Ending Balance | $ 2,853,000 | $ 2,853,000 | $ 3,046,000 | |||||
Depreciation, Depletion and Amortization, Total | 651,000 | $ 547,000 | ||||||
Assets Leased to Others [Member] | ||||||||
Property, Plant and Equipment, Net, Ending Balance | 1,087,000 | 1,087,000 | ||||||
Depreciation, Depletion and Amortization, Total | $ 115,000 | $ 228,000 | ||||||
Sublease Agreement for Relocation of Headquarters [Member] | ||||||||
Area of Real Estate Property (Square Foot) | ft² | 12,400 | |||||||
Operating Leases, Monthly Rent Per Rentable Square Foot During First Year | 20.5 | |||||||
Operating Leases, Monthly Rent Per Rentable Square Foot During Second Year | 21.12 | |||||||
Operating Leases, Monthly Rent Per Rentable Square Foot During Third Year | 21.75 | |||||||
Security Deposit | $ 22,000 | |||||||
Operating Leases, Allowance for Certain Improvements | $ 88,000 | |||||||
Noncancelable Operating Lease Agreement for Office Equipment [Member] | ||||||||
Lessee, Operating Lease, Term of Contract (Month) | 3 years | |||||||
Operating Leases, Monthly Payment | $ 3,000 | |||||||
[1] | The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date. |
Note 8 - Leases - Lease Assets
Note 8 - Leases - Lease Assets and Liabilities (Details) - USD ($) $ in Thousands | Jun. 30, 2020 | Dec. 31, 2019 |
Operating lease right-of-use assets | $ 267 | $ 395 |
Accrued Liabilities [Member] | ||
Current operating lease liabilities | 265 | 268 |
Other Noncurrent Liabilities [Member] | ||
Noncurrent operating lease liabilities | 7 | 132 |
Accrued Liabilities and Other Noncurrent Liabilities [Member] | ||
Operating Lease, Liability, Total | $ 272 | $ 400 |
Note 8 - Leases - Maturity of O
Note 8 - Leases - Maturity of Operating Lease Liabilities (Details) - USD ($) $ in Thousands | Jun. 30, 2020 | Dec. 31, 2019 |
2020 (remaining 6 months) | $ 153 | |
2021 | 137 | |
Total lease payments | 290 | |
Less: Amount representing interest | (18) | |
Accrued Liabilities and Other Noncurrent Liabilities [Member] | ||
Present value of lease liabilities | $ 272 | $ 400 |
Note 8 - Leases - Minimum Futur
Note 8 - Leases - Minimum Future Rentals (Details) $ in Thousands | Jun. 30, 2020USD ($) |
2020 (remaining 6 months) | $ 698 |
2021 | 106 |
Thereafter | |
Total | $ 804 |
Note 10 - Preferred Stock (Deta
Note 10 - Preferred Stock (Details Textual) - USD ($) | Nov. 26, 2019 | Nov. 12, 2019 | Feb. 29, 2020 | Jan. 31, 2020 | Jun. 30, 2020 | Jun. 30, 2020 | Dec. 31, 2019 | Nov. 30, 2019 | |
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 23,583,290 | 23,583,290 | |||||||
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | |||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 9,893,776 | 9,893,776 | |||||||
Conversion of Term Loan with CRG Into Series B Convertible Preferred Stock [Member] | |||||||||
Debt Conversion, Converted Instrument, Shares Issued (in shares) | 31,300 | 31,300 | |||||||
Series A Convertible Preferred Stock Into Common Stock [Member] | |||||||||
Conversion of Stock, Shares Converted (in shares) | 669,022 | 1,183,151 | |||||||
Series A Preferred Stock [Member] | |||||||||
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | 1 | 1 | 1 | ||||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | 0 | 0 | 1,852,173 | ||||||
Series A Convertible Preferred Stock [Member] | |||||||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | 0 | 0 | |||||||
Series B Preferred Stock [Member] | |||||||||
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | 22,016,179 | 22,016,179 | |||||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | 33,685 | 33,685 | 31,678 | [1] | |||||
Preferred Stock, Dividend Rate, Percentage | 12.50% | ||||||||
Preferred Stock Dividends, Shares (in shares) | 1,018 | 2,007 | 378 | ||||||
Dividends, Preferred Stock, Cash | $ 3,000 | $ 4,000 | $ 2,000 | ||||||
Preferred Stock, Fair Value, Per Share (in dollars per share) | $ 1,023.23 | ||||||||
Convertible Preferred Stock, Fair Value | $ 32,027,000 | ||||||||
Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares) | 31,300 | ||||||||
[1] | The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date. |
Note 11 - Common Stock (Details
Note 11 - Common Stock (Details Textual) | Jun. 09, 2020USD ($)$ / sharesshares | Jun. 08, 2020USD ($) | Apr. 20, 2020USD ($)$ / sharesshares | Apr. 16, 2020USD ($)shares | Jun. 30, 2020USD ($)$ / sharesshares | May 31, 2020USD ($)shares | Mar. 31, 2020USD ($)shares | Feb. 29, 2020USD ($)shares | Nov. 30, 2019USD ($)$ / sharesshares | Jun. 30, 2020USD ($)$ / sharesshares | Mar. 31, 2020USD ($)shares | Jun. 30, 2019USD ($)shares | Mar. 31, 2019USD ($)shares | Jun. 30, 2020USD ($)$ / sharesshares | Jun. 30, 2019USD ($)shares | Nov. 30, 2019$ / sharesshares | Apr. 15, 2020$ / shares | Dec. 31, 2019$ / sharesshares | Nov. 26, 2019shares | Nov. 12, 2019USD ($)$ / sharesshares | May 22, 2017USD ($)$ / sharesshares | |
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 23,583,290 | 23,583,290 | 23,583,290 | |||||||||||||||||||
Stock Issued During Period, Share, Restricted Common Shares (in shares) | 34,531 | 28,313 | ||||||||||||||||||||
Stock Issued During Period, Value, Restricted Common Shares | $ | $ 25,000 | $ 24,000 | $ 25,000 | $ 24,000 | $ 25,000 | |||||||||||||||||
Proceeds from Warrant Exercises | $ | $ 4,800,000 | |||||||||||||||||||||
Fair Value Adjustment of Warrants | $ | 1,838,000 | 1,838,000 | ||||||||||||||||||||
Payments of Warrant Issuance Costs | $ | $ 326,000 | 326,000 | ||||||||||||||||||||
Amortization of Debt Discount (Premium) | $ | 1,000 | $ 119,000 | 2,000 | $ 202,000 | ||||||||||||||||||
Debt Instrument, Unamortized Discount, Total | $ | 10,000 | $ 10,000 | $ 10,000 | |||||||||||||||||||
Class of Warrant or Right Number of Securities Called by Warrants or Rights Cancelled In Period (in shares) | 0 | 0 | 0 | 0 | ||||||||||||||||||
Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights Expired In Period (in shares) | 215 | 0 | 215 | 0 | ||||||||||||||||||
The 2017 Loan Agreement [Member] | ||||||||||||||||||||||
Debt Issuance Costs, Net, Total | $ | 790,000 | $ 790,000 | $ 790,000 | |||||||||||||||||||
Debt Instrument, Unamortized Discount, Total | $ | $ 10,000 | $ 10,000 | $ 10,000 | |||||||||||||||||||
Series B Convertible Preferred Stock Into Common Stock [Member] | Minimum [Member] | ||||||||||||||||||||||
Conversion of Stock, Conversion Rate (in dollars per share) | $ / shares | $ 1.53 | |||||||||||||||||||||
Series B Convertible Preferred Stock Into Common Stock [Member] | Maximum [Member] | ||||||||||||||||||||||
Conversion of Stock, Conversion Rate (in dollars per share) | $ / shares | $ 1.836 | |||||||||||||||||||||
Series A Preferred Stock [Member] | ||||||||||||||||||||||
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | 1 | 1 | 1 | 1 | 1 | |||||||||||||||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | 0 | 0 | 0 | 1,852,173 | ||||||||||||||||||
Series B Preferred Stock [Member] | ||||||||||||||||||||||
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | 22,016,179 | 22,016,179 | 22,016,179 | |||||||||||||||||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | 33,685 | 33,685 | 33,685 | 31,678 | [1] | |||||||||||||||||
Conversion of Stock, Conversion Rate (in dollars per share) | $ / shares | $ 1.53 | $ 1.53 | $ 1.53 | |||||||||||||||||||
Series A Warrants [Member] | ||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | 1 | ||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 1.55 | $ 1.55 | ||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 1 year | 1 year | ||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 1,540,829 | 7,419,353 | 1,540,829 | 1,540,829 | 7,419,353 | |||||||||||||||||
Stock Issued During Period, Shares, Warrant Exercises (in shares) | 4,820,584 | 27,601 | 4,099 | 1,026,240 | ||||||||||||||||||
Proceeds from Warrant Exercises | $ | $ 17,000 | $ 2,500 | $ 1,591,000 | |||||||||||||||||||
Series B Warrants [Member] | ||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | 1 | ||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 1.55 | $ 1.55 | ||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | 5 years | ||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 7,080,390 | 7,419,353 | 7,080,390 | 7,080,390 | 7,419,353 | |||||||||||||||||
Stock Issued During Period, Shares, Warrant Exercises (in shares) | 242,790 | 50,700 | 45,473 | |||||||||||||||||||
Proceeds from Warrant Exercises | $ | $ 31,000 | $ 70,000 | ||||||||||||||||||||
Series A and Series B Warrants [Member] | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.61 | $ 1.55 | ||||||||||||||||||||
Proceeds from Warrant Exercises | $ | $ 3,089,000 | |||||||||||||||||||||
Series A-2 Warrants [Member] | ||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 4,820,584 | |||||||||||||||||||||
Series B-2 Warrants [Member] | ||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 242,790 | |||||||||||||||||||||
Series A-2 and Series B-2 Warrants [Member] | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.6371 | |||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||||||||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 1,838,000 | |||||||||||||||||||||
Series A-2 and Series B-2 Warrants [Member] | Measurement Input, Expected Dividend Rate [Member] | ||||||||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 0 | |||||||||||||||||||||
Series A-2 and Series B-2 Warrants [Member] | Measurement Input, Price Volatility [Member] | ||||||||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 0.841 | |||||||||||||||||||||
Series A-2 and Series B-2 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | ||||||||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 0.0035 | |||||||||||||||||||||
Series A-2 and Series B-2 Warrants [Member] | Measurement Input, Expected Term [Member] | ||||||||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 5 | |||||||||||||||||||||
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | ||||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 9,893,776 | 9,893,776 | ||||||||||||||||||||
Class of Warrants or Rights, Outstanding, Percentage of Common Stock | 15.00% | |||||||||||||||||||||
Class of Warrants and Rights Outstanding, Exercise Price Percentage of Conversion Rate | 120.00% | |||||||||||||||||||||
Warrants and Rights Outstanding | $ | $ 3,502,000 | $ 3,502,000 | $ 3,502,000 | $ 3,502,000 | ||||||||||||||||||
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | Measurement Input, Expected Dividend Rate [Member] | ||||||||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 0 | |||||||||||||||||||||
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | Measurement Input, Price Volatility [Member] | ||||||||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 0.688 | |||||||||||||||||||||
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | Measurement Input, Risk Free Interest Rate [Member] | ||||||||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 0.0158 | |||||||||||||||||||||
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | Measurement Input, Expected Term [Member] | ||||||||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 5 | |||||||||||||||||||||
May 2017 Issuance Related to 2017 Loan Agreement [Member] | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 950 | |||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 10 years | |||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 2,220 | |||||||||||||||||||||
Warrants and Rights Outstanding | $ | $ 940,000 | |||||||||||||||||||||
Class A Units [Member] | Series A Warrants [Member] | ||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | 1 | ||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 1.55 | $ 1.55 | ||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 1 year | 1 year | ||||||||||||||||||||
Class A Units [Member] | Series B Warrants [Member] | ||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | 1 | ||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 1.55 | $ 1.55 | ||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | 5 years | ||||||||||||||||||||
Class B Units [Member] | Series A Warrants [Member] | ||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | 1 | ||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 1.55 | $ 1.55 | ||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 1 year | 1 year | ||||||||||||||||||||
Class B Units [Member] | Series B Warrants [Member] | ||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | 1 | ||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 1.55 | $ 1.55 | ||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | 5 years | ||||||||||||||||||||
Common Stock [Member] | ||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 525,000 | |||||||||||||||||||||
Stock Issued During Period, Share, Restricted Common Shares (in shares) | 34,531 | 28,313 | 274 | |||||||||||||||||||
Stock Issued During Period, Value, Restricted Common Shares | $ | ||||||||||||||||||||||
Common Stock [Member] | Series A Warrants [Member] | ||||||||||||||||||||||
Stock Issued During Period, Shares, Warrant Exercises (in shares) | 4,852,284 | 1,026,240 | ||||||||||||||||||||
Common Stock [Member] | Series B Warrants [Member] | ||||||||||||||||||||||
Stock Issued During Period, Shares, Warrant Exercises (in shares) | 293,490 | 45,473 | ||||||||||||||||||||
Purchase Agreement with LPC [Member] | ||||||||||||||||||||||
Maximum Amount of Shares Issuable | $ | $ 10,000,000 | $ 10,000,000 | ||||||||||||||||||||
Stock Purchase Agreement Duration Period (Month) | 2 years 180 days | 2 years 180 days | ||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 525,000 | |||||||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 0.65 | |||||||||||||||||||||
Maximum Number of Shares Issuable on Any Business Day Selected by The Company (in shares) | 250,000 | |||||||||||||||||||||
Maximum Number of Shares Issuable on Regular Purchase, Closing Sale Price Not Below $1.00 (in shares) | 300,000 | |||||||||||||||||||||
Maximum Number of Shares Issuable on Regular Purchase, Closing Sale Price Not Below $2.00 (in shares) | 500,000 | |||||||||||||||||||||
Maximum Number of Shares Issuable Any single Regular Purchase (in shares) | 1,000,000 | |||||||||||||||||||||
Payments of Stock Issuance Costs | $ | $ 452,000 | 452,000 | ||||||||||||||||||||
Purchase Agreement with LPC [Member] | Commitment Fee [Member] | ||||||||||||||||||||||
Payments of Stock Issuance Costs | $ | $ 325,000 | |||||||||||||||||||||
November 2019 Offering [Member] | ||||||||||||||||||||||
Payments of Stock Issuance Costs | $ | $ 33,000 | |||||||||||||||||||||
Proceeds from Issuance or Sale of Equity, Total | $ | $ 11,500,000 | |||||||||||||||||||||
Proceeds From Issuance of Common Stock, Net | $ | $ 9,922,000 | |||||||||||||||||||||
November 2019 Offering [Member] | Series A Preferred Stock [Member] | ||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 5,473,410 | |||||||||||||||||||||
November 2019 Offering [Member] | Series B Preferred Stock [Member] | ||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 5,473,410 | |||||||||||||||||||||
November 2019 Offering [Member] | Class A Units [Member] | ||||||||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 1.55 | $ 1.55 | ||||||||||||||||||||
Common Shares Per Unit (in shares) | 1 | 1 | ||||||||||||||||||||
November 2019 Offering [Member] | Class B Units [Member] | ||||||||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 1.55 | $ 1.55 | ||||||||||||||||||||
Series A Convertible Preferred Stock Per Unit (in shares) | 1 | 1 | ||||||||||||||||||||
November 2019 Offering [Member] | Common Stock [Member] | ||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 1,945,943 | 1,945,943 | ||||||||||||||||||||
[1] | The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date. |
Note 11 - Common Stock - Summar
Note 11 - Common Stock - Summary of Outstanding Warrants (Details) | 6 Months Ended |
Jun. 30, 2020$ / sharesshares | |
Shares Outstanding Under Warrants (in shares) | 23,583,290 |
Warrant One [Member] | |
Expiration Date | Feb. 17, 2025 |
Exercise Price (in dollars per share) | $ / shares | $ 400 |
Shares Outstanding Under Warrants (in shares) | 754 |
Warrant Two [Member] | |
Expiration Date | Mar. 26, 2025 |
Exercise Price (in dollars per share) | $ / shares | $ 272 |
Shares Outstanding Under Warrants (in shares) | 14 |
Warrant Three [Member] | |
Expiration Date | May 12, 2025 |
Exercise Price (in dollars per share) | $ / shares | $ 424 |
Shares Outstanding Under Warrants (in shares) | 362 |
Warrant Four [Member] | |
Expiration Date | Dec. 16, 2025 |
Exercise Price (in dollars per share) | $ / shares | $ 560 |
Shares Outstanding Under Warrants (in shares) | 267 |
Warrant Five [Member] | |
Expiration Date | Apr. 1, 2026 |
Exercise Price (in dollars per share) | $ / shares | $ 608 |
Shares Outstanding Under Warrants (in shares) | 250 |
Warrant Six [Member] | |
Expiration Date | May 11, 2021 |
Exercise Price (in dollars per share) | $ / shares | $ 774 |
Shares Outstanding Under Warrants (in shares) | 50 |
Warrant Seven [Member] | |
Expiration Date | Jun. 20, 2026 |
Exercise Price (in dollars per share) | $ / shares | $ 498 |
Shares Outstanding Under Warrants (in shares) | 1,004 |
Warrant Eight [Member] | |
Expiration Date | May 25, 2027 |
Exercise Price (in dollars per share) | $ / shares | $ 950 |
Shares Outstanding Under Warrants (in shares) | 2,220 |
Warrant Nine [Member] | |
Expiration Date | Nov. 26, 2020 |
Exercise Price (in dollars per share) | $ / shares | $ 0.61 |
Shares Outstanding Under Warrants (in shares) | 1,540,829 |
Warrant Ten [Member] | |
Expiration Date | Nov. 26, 2024 |
Exercise Price (in dollars per share) | $ / shares | $ 0.61 |
Shares Outstanding Under Warrants (in shares) | 7,080,390 |
Warrant Eleven [Member] | |
Expiration Date | Nov. 26, 2024 |
Exercise Price (in dollars per share) | $ / shares | $ 1.836 |
Shares Outstanding Under Warrants (in shares) | 9,893,776 |
Warrant Twelve [Member] | |
Expiration Date | Apr. 21, 2025 |
Exercise Price (in dollars per share) | $ / shares | $ 0.6371 |
Shares Outstanding Under Warrants (in shares) | 5,063,374 |
Note 11 - Common Stock - Assump
Note 11 - Common Stock - Assumptions (Details) - Warrant [Member] | Apr. 15, 2020 | Apr. 14, 2020 |
Measurement Input, Exercise Price [Member] | ||
Warrants and Rights Outstanding, Measurement Input | 0.61 | 1.55 |
Measurement Input, Share Price [Member] | ||
Warrants and Rights Outstanding, Measurement Input | 0.63 | 0.63 |
Measurement Input, Expected Term [Member] | ||
Warrants and Rights Outstanding, Measurement Input | 2.8 | 2.8 |
Measurement Input, Price Volatility [Member] | ||
Warrants and Rights Outstanding, Measurement Input | 0.0097 | 0.0094 |
Measurement Input, Risk Free Interest Rate [Member] | ||
Warrants and Rights Outstanding, Measurement Input | 0.000027 | 0.000027 |
Measurement Input, Expected Dividend Rate [Member] | ||
Warrants and Rights Outstanding, Measurement Input | 0 | 0 |
Note 12 - Summary of Stock Op_3
Note 12 - Summary of Stock Options (Details Textual) - USD ($) | Mar. 31, 2020 | Jan. 01, 2020 | Jun. 30, 2020 | Jul. 31, 2019 | Jun. 30, 2019 | Apr. 30, 2019 | Jan. 31, 2019 | Jun. 30, 2020 | Mar. 31, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | Dec. 31, 2019 | Nov. 26, 2019 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) | 10,023,441 | 10,023,441 | 10,023,441 | 10,087,678 | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share) | $ 1.97 | $ 1.97 | $ 1.97 | $ 2.22 | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year) | 9 years 146 days | 9 years 328 days | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 468,000 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares) | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | 0.00% | 0.00% | 0.00% | |||||||||||
Consultant [Member] | ||||||||||||||
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares) | 250 | 250 | ||||||||||||
Director [Member] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 525 | |||||||||||||
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares) | 378 | 525 | ||||||||||||
Restricted Stock [Member] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares) | 2,348 | 2,348 | 2,348 | |||||||||||
Restricted Stock [Member] | Director [Member] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ 38.08 | $ 91 | ||||||||||||
Share-based Payment Arrangement, Option [Member] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | 0.00% | |||||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ 5,819,000 | $ 5,819,000 | $ 5,819,000 | |||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 2 years 328 days | |||||||||||||
The 2006 Stock Option Plan [Member] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) | 104 | 104 | 104 | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares) | 0 | 0 | 0 | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share) | $ 992 | $ 992 | $ 992 | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year) | 2 years 219 days | |||||||||||||
The 2013 Plan [Member] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) | 10,023,337 | 10,023,337 | 10,023,337 | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares) | 4,502,522 | 4,502,522 | 4,502,522 | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share) | $ 1.97 | $ 1.97 | $ 1.97 | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year) | 9 years 146 days | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares) | 2,639,926 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) | 14,512,457 | 11,872,531 | ||||||||||||
The 2013 Plan [Member] | Employees [Member] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 0 | 1,900 | 468,000 | 23,350 | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ 32.77 | $ 0.52 | $ 71.77 | |||||||||||
The 2013 Plan [Member] | Nonemployees [Member] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares) | 0 | 0 | 0 | 0 | ||||||||||
The 2013 Plan [Member] | Restricted Stock [Member] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 3,625 | 0 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period (in shares) | 22 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares) | 0 | |||||||||||||
2017 Employee Stock Purchase Plan [Member] | ||||||||||||||
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares) | 320 | 300 | ||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 0.59 | $ 0.48 | $ 0.48 | $ 0.59 | $ 0.48 | |||||||||
Employee Stock Ownership Plan (ESOP), Number of Suspense Shares (in shares) | 472 | 472 | 472 | |||||||||||
Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased (in dollars per share) | $ 0.23 | $ 0.95 | $ 0.33 | $ 0.68 | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | 0.00% | 0.00% | 0.00% | 0.00% |
Note 12 - Summary of Stock Op_4
Note 12 - Summary of Stock Options - Summary of Option Activity Under All Plans (Details) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2020USD ($)$ / sharesshares | Dec. 31, 2019USD ($)$ / sharesshares | |
Options outstanding, beginning of period (in shares) | shares | 10,087,678 | |
Options outstanding, weighted average exercise price (in dollars per share) | $ / shares | $ 2.22 | |
Options outstanding, weighted average remaining contractual term (Year) | 9 years 146 days | 9 years 328 days |
Options outstanding, aggregate intrinsic value | $ | $ 3,928,715 | |
Options granted (in shares) | shares | 468,000 | |
Options granted, weighted average exercise price (in dollars per share) | $ / shares | $ 0.88 | |
Options exercised (in shares) | shares | ||
Options exercised, weighted average exercise price (in dollars per share) | $ / shares | ||
Options canceled (in shares) | shares | (532,237) | |
Options canceled, weighted average exercise price (in dollars per share) | $ / shares | $ 5.81 | |
Options outstanding, end of period (in shares) | shares | 10,023,441 | 10,087,678 |
Options outstanding, weighted average exercise price (in dollars per share) | $ / shares | $ 1.97 | $ 2.22 |
Vested and exercisable and expected to vest, end of period (in shares) | shares | 9,164,577 | |
Vested and exercisable and expected to vest, end of period, weighted average exercise price (in dollars per share) | $ / shares | $ 2.06 | |
Vested and exercisable and expected to vest, end of period, weighted average remaining contractual term (Year) | 9 years 146 days | |
Vested and exercisable and expected to vest, end of period, aggregate intrinsic value | $ | ||
Vested and exercisable, end of period (in shares) | shares | 1,447,596 | |
Vested and exercisable, end of period, weighted average exercise price (in dollars per share) | $ / shares | $ 6.41 | |
Vested and exercisable, end of period, weighted average remaining contractual term (Year) | 9 years 36 days | |
Vested and exercisable, end of period, aggregate intrinsic value | $ |
Note 12 - Summary of Stock Op_5
Note 12 - Summary of Stock Options - Summary of Options Outstanding and Exercisable (Details) | 6 Months Ended |
Jun. 30, 2020$ / sharesshares | |
Options outstanding, number (in shares) | shares | 10,023,441 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 1.97 |
Options outstanding, weighted average remaining contractual term (Year) | 9 years 146 days |
Options exercisable, number exercisable (in shares) | shares | 1,447,596 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 6.41 |
Range One [Member] | |
Exercise price range, lower limit (in dollars per share) | 0.69 |
Exercise price range, upper limit (in dollars per share) | $ 0.89 |
Options outstanding, number (in shares) | shares | 9,830,708 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 0.86 |
Options outstanding, weighted average remaining contractual term (Year) | 9 years 146 days |
Options exercisable, number exercisable (in shares) | shares | 1,410,939 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 0.87 |
Range Two [Member] | |
Exercise price range, lower limit (in dollars per share) | 1.09 |
Exercise price range, upper limit (in dollars per share) | $ 1.36 |
Options outstanding, number (in shares) | shares | 155,000 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 1.26 |
Options outstanding, weighted average remaining contractual term (Year) | 9 years 255 days |
Options exercisable, number exercisable (in shares) | shares | 12,500 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 1.36 |
Range Three [Member] | |
Exercise price range, lower limit (in dollars per share) | 38 |
Exercise price range, upper limit (in dollars per share) | $ 58 |
Options outstanding, number (in shares) | shares | 1,250 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 55.20 |
Options outstanding, weighted average remaining contractual term (Year) | 8 years 328 days |
Options exercisable, number exercisable (in shares) | shares | 1,103 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 57.17 |
Range Four [Member] | |
Exercise price range, lower limit (in dollars per share) | 100 |
Exercise price range, upper limit (in dollars per share) | $ 197 |
Options outstanding, number (in shares) | shares | 20,289 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 141.91 |
Options outstanding, weighted average remaining contractual term (Year) | 8 years 146 days |
Options exercisable, number exercisable (in shares) | shares | 10,650 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 146.21 |
Range Five [Member] | |
Exercise price range, lower limit (in dollars per share) | 202 |
Exercise price range, upper limit (in dollars per share) | $ 283 |
Options outstanding, number (in shares) | shares | 725 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 250.69 |
Options outstanding, weighted average remaining contractual term (Year) | 7 years 182 days |
Options exercisable, number exercisable (in shares) | shares | 412 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 253.75 |
Range Six [Member] | |
Exercise price range, lower limit (in dollars per share) | 311 |
Exercise price range, upper limit (in dollars per share) | $ 382 |
Options outstanding, number (in shares) | shares | 2,134 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 344.37 |
Options outstanding, weighted average remaining contractual term (Year) | 7 years 36 days |
Options exercisable, number exercisable (in shares) | shares | 1,511 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 347 |
Range Seven [Member] | |
Exercise price range, lower limit (in dollars per share) | 430 |
Exercise price range, upper limit (in dollars per share) | $ 497 |
Options outstanding, number (in shares) | shares | 6,687 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 454.20 |
Options outstanding, weighted average remaining contractual term (Year) | 7 years |
Options exercisable, number exercisable (in shares) | shares | 4,652 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 455.41 |
Range Eight [Member] | |
Exercise price range, lower limit (in dollars per share) | 501 |
Exercise price range, upper limit (in dollars per share) | $ 567 |
Options outstanding, number (in shares) | shares | 3,215 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 537.49 |
Options outstanding, weighted average remaining contractual term (Year) | 6 years 328 days |
Options exercisable, number exercisable (in shares) | shares | 2,610 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 536.64 |
Range Nine [Member] | |
Exercise price range, lower limit (in dollars per share) | 600 |
Exercise price range, upper limit (in dollars per share) | $ 661 |
Options outstanding, number (in shares) | shares | 1,392 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 602.19 |
Options outstanding, weighted average remaining contractual term (Year) | 5 years 182 days |
Options exercisable, number exercisable (in shares) | shares | 1,378 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 601.59 |
Range Ten [Member] | |
Exercise price range, lower limit (in dollars per share) | 700 |
Exercise price range, upper limit (in dollars per share) | $ 792 |
Options outstanding, number (in shares) | shares | 1,937 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 767.72 |
Options outstanding, weighted average remaining contractual term (Year) | 6 years 109 days |
Options exercisable, number exercisable (in shares) | shares | 1,737 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 767.32 |
Range Eleven [Member] | |
Exercise price range, lower limit (in dollars per share) | 992 |
Exercise price range, upper limit (in dollars per share) | $ 992 |
Options outstanding, number (in shares) | shares | 104 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 992 |
Options outstanding, weighted average remaining contractual term (Year) | 2 years 219 days |
Options exercisable, number exercisable (in shares) | shares | 104 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 992 |
Note 12 - Summary of Stock Op_6
Note 12 - Summary of Stock Options - Valuation Assumption for Employee Stock Purchase Plan (Details) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | |
Expected term (Year) | 5 years | 5 years | 5 years | |
Average volatility | 75.00% | 73.00% | 73.00% | |
Risk-free interest rate | 2.03% | 0.45% | 2.49% | |
Dividend yield | 0.00% | 0.00% | 0.00% | |
2017 Employee Stock Purchase Plan [Member] | ||||
Expected term (Year) | 91 days | 91 days | 91 days | 91 days |
Average volatility | 110.00% | 87.00% | 117.00% | 81.00% |
Risk-free interest rate | 0.09% | 2.43% | 0.84% | 2.44% |
Dividend yield | 0.00% | 0.00% | 0.00% | 0.00% |
Note 12 - Summary of Stock Op_7
Note 12 - Summary of Stock Options - Valuation Assumptions for Stock Options (Details) | 3 Months Ended | 6 Months Ended | |
Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | |
Expected term (Year) | 5 years | 5 years | 5 years |
Average volatility | 75.00% | 73.00% | 73.00% |
Risk-free interest rate | 2.03% | 0.45% | 2.49% |
Dividend yield | 0.00% | 0.00% | 0.00% |
Note 12 - Summary of Stock Op_8
Note 12 - Summary of Stock Options - Stock-based Compensation Expense Included in the Statement of Income (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | |
Stock-based compensation expense | $ 658 | $ 621 | $ 1,367 | $ 1,117 |
Cost of Sales [Member] | ||||
Stock-based compensation expense | 61 | 34 | 121 | 66 |
Research and Development Expense [Member] | ||||
Stock-based compensation expense | 85 | 53 | 171 | 93 |
Selling, General and Administrative Expenses [Member] | ||||
Stock-based compensation expense | $ 512 | $ 534 | $ 1,075 | $ 958 |
Note 13 - Income Taxes (Details
Note 13 - Income Taxes (Details Textual) - USD ($) xbrli-pure in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended |
Jun. 30, 2020 | Jun. 30, 2020 | Dec. 31, 2020 | |
Income Tax Expense (Benefit), Total | $ 0 | ||
Effective Income Tax Rate Reconciliation, Percent, Total | 0.00% | 0.00% | |
Forecast [Member] | |||
Effective Income Tax Rate Reconciliation, Percent, Total | 0.00% |
Note 14 - Related Party Trans_2
Note 14 - Related Party Transactions (Details Textual) - Stellartech Research Corporation [Member] - USD ($) | 3 Months Ended | 6 Months Ended | 129 Months Ended | |||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Dec. 31, 2019 | |
Stock Issued During Period, Shares, New Issues (in shares) | 375 | |||||
Related Party Transaction, Amounts of Transaction | $ 467,000 | $ 1,820,000 | $ 749,000 | $ 3,132,000 | ||
Accounts Payable, Related Parties, Current | $ 165,000 | $ 165,000 | $ 165,000 | $ 124,000 |
Note 15 - Restructuring Costs (
Note 15 - Restructuring Costs (Details Textual) | 1 Months Ended | 3 Months Ended | 6 Months Ended | ||
Jan. 31, 2019USD ($) | Jun. 30, 2020USD ($) | Jun. 30, 2019USD ($) | Jun. 30, 2020USD ($) | Jun. 30, 2019USD ($) | |
Restructuring and Related Cost, Number of Positions Eliminated | 40 | ||||
Restructuring Charges, Total | $ 742,000 | $ 742,000 |